1236 genotypes with 1778 annotations displayed
of selected term and subterms
|
Searched Term: increased gland tumor incidence
|
Acp3tm1Pivi/Acp3tm1Pivi
(B6.Cg-Acp3tm1Pivi)
|
increased prostate gland adenocarcinoma incidence
|
J:207558
|
increased prostate intraepithelial neoplasia incidence
|
J:207558
|
Actbtm1(PyVT)Arge/Actb+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:87544
|
Actbtm1(PyVT)Arge/Actb+ Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:87544
|
Adipoqtm1Chan/Adipoq+ Tg(MMTV-PyVT)634Mul/0
(B6.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:147458
|
Adipoqtm1Chan/Adipoq+ Tg(MMTV-PyVT)634Mul/0
(FVB.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:147458
|
Ahrtm1Bra/Ahr+ Tg(TRAMP)8247Ng/0
(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
|
increased prostate gland tumor incidence
|
J:118152
|
Ahrtm1Bra/Ahrtm1Bra Tg(TRAMP)8247Ng/0
(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
|
increased prostate gland tumor incidence
|
J:118152
|
Aicdatm1(cre)Mnz/Aicda+ Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:153656
|
AipGt(RRI002)Byg/Aip+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary adenoma incidence
|
J:165349
|
increased prolactinoma incidence
|
J:165349
|
Akt1Gt1Pnt/Akt1Gt1Pnt Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt1Gt1Pnt/Akt1Gt1Pnt Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt3tm1Mbb/Akt3tm1Mbb Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt3tm1Mbb/Akt3tm1Mbb Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Aldh2tm1a(EUCOMM)Wtsi/Aldh2tm1a(EUCOMM)Wtsi Fancd2tm1Hou/Fancd2tm1Hou
(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
|
increased T cell derived lymphoma incidence
|
J:193232
|
Amhtm1Bhr/Amh+ Amhr2tm1Bhr/Amhr2tm1Bhr
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased testis tumor incidence
|
J:36027
|
Amhr2tm1Bhr/Amhr2tm1Bhr Inhatm1Bay/Inha+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased testis tumor incidence
|
J:36027
|
Amhr2tm1Bhr/Amhr2tm1Bhr Inhatm1Bay/Inhatm1Bay
(involves: 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:36027
|
increased Leydig cell tumor incidence
|
J:36027
|
increased testis tumor incidence
|
J:36027
|
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S/SvEv * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
increased ovary tumor incidence
|
J:128934
|
increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased testis tumor incidence
|
J:186144
|
Amhr2tm3(cre)Bhr/Amhr2+ Ctnnb1tm1Mmt/Ctnnb1+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ)
|
increased granulosa cell tumor incidence
|
J:149060
|
increased ovary tumor incidence
|
J:142150
|
increased testis tumor incidence
|
J:149060
|
Amhr2tm3(cre)Bhr/Amhr2+ Ctnnb1tm1Mmt/Ctnnb1+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased testis tumor incidence
|
J:186144
|
Amhr2tm3(cre)Bhr/Amhr2+ KitW-v/KitW-v Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J * FVB/N)
|
increased granulosa cell tumor incidence
|
J:236161
|
increased ovary adenoma incidence
|
J:236161
|
increased ovary tumor incidence
|
J:236161
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2.1Rob Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
increased ovary tumor incidence
|
J:128934
|
increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2.1Rob Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Zuk
(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
increased ovary tumor incidence
|
J:128934
|
increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Zuk
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Zuk Smad9tm1Jfm/Smad9tm1Jfm
(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
increased ovary tumor incidence
|
J:128934
|
ApcM1Tno/Apc+
(involves: C57BL/6 * DBA/2JJcl)
|
increased mammary gland tumor incidence
|
J:218227
|
ApcM1Tno/Apc+
(either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl))
|
increased mammary adenocarcinoma incidence
|
J:218227
|
increased mammary gland tumor incidence
|
J:218227
|
ApcMin/Apc+
(involves: C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:94108
|
ApcMin/Apc+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased mammary gland tumor incidence
|
J:67445
|
ApcMin/Apc+
(B6(AKR)-ApcMin)
|
increased mammary gland tumor incidence
|
J:15101
|
ApcMin/Apc+ Brca2tm1Mbn/Brca2+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased mammary gland tumor incidence
|
J:67445
|
ApcMin/Apc+ Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased mammary adenoacanthoma incidence
|
J:57721
|
increased salivary gland tumor incidence
|
J:57721
|
ApcMin/Apc+ Trp53tm1Mlh/Trp53tm1Mlh
(involves: 129P2/OlaHsd * C57BL/6 * SWR)
|
increased pancreatic acinar cell carcinoma incidence
|
J:29664
|
Apctm1Cip/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:94108
|
Apctm1Hsa/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:61978
|
increased mammary gland tumor incidence
|
J:61978
|
Apctm1Mmt/Apc+ Smad4tm1Mmt/Smad4+
(involves: 129S2/SvPas * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:46242
|
Apctm1Rsmi/Apctm1Rsmi Pgrtm2(cre)Lyd/Pgr+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:210095
|
increased ovary tumor incidence
|
J:210095
|
Apctm1Tno/Apc+ Brf1tm1Arte/Brf1tm1Arte Tg(Cyp1a1-cre)1Dwi/0
(involves: C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Apctm1Tno/Apc+ Tg(CDX2-cre)101Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:126018
|
Apctm1Tno/Apctm1Tno Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased ovarian carcinoma incidence
|
J:120955
|
Apctm1Tno/Apctm1Tno Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:120308
|
increased prostate intraepithelial neoplasia incidence
|
J:120308
|
Apctm2Rak/Apc+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)6Tuv/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
|
increased pancreas tumor incidence
|
J:234310
|
Apctm2Rfo/Apc+
(B6.129P2-Apctm2Rfo)
|
increased mammary adenocarcinoma incidence
|
J:151494
|
increased mammary gland tumor incidence
|
J:151494
|
Apctm2Rfo/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
|
increased mammary adenocarcinoma incidence
|
J:204440,
J:151494
|
increased mammary gland tumor incidence
|
J:151494
|
Apctm2Rfo/Apc+
(129P2/OlaHsd-Apctm2Rfo)
|
increased mammary adenocarcinoma incidence
|
J:151494
|
Apctm2Rfo/Apc+ Smad4E6sad/Smad4+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:151494
|
Apmt1FVB/NJ/Apmt1FVB/NJ
(involves: FVB/NJ * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt1FVB/NJ/Apmt1FVB/NJ Apmt2I/LnJ/Apmt2FVB/NJ
(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt1FVB/NJ/Apmt1I/LnJ
(involves: FVB/NJ * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt2I/LnJ/?
(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
ArTfm/Y
(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
|
increased testis tumor incidence
|
J:140803
|
ArTfm/Y Tg(TSPY)9Jshm/0
(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
|
increased testis tumor incidence
|
J:140803
|
Artm1(AR)Dmr/Y Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Artm1Verh/Y Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:172730
|
Artm2(AR)Dmr/Y Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Artm3.1(AR)Ska/Y Tg(KLKB1-cre/ERT2)1Pcn/0 Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
increased prostate gland tumor incidence
|
J:170092
|
Arid1atm1.1Mag/Arid1atm1.1Mag Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * CD-1)
|
increased ovarian carcinoma incidence
|
J:219794
|
increased ovary tumor incidence
|
J:219794
|
Atad5Gt(RRF055)Byg/Atad5+
(involves: 129P2/OlaHsd)
|
increased gland tumor incidence
|
J:176672
|
increased granulosa cell tumor incidence
|
J:176672
|
increased Harderian gland adenocarcinoma incidence
|
J:176672
|
increased T cell derived lymphoma incidence
|
J:176672
|
Atmtm1.1Mmpl/Atmtm1.1Mmpl
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:226414
|
Atmtm1Awb/Atmtm1Awb
(either: 129S6/SvEvTac-Atmtm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
increased T cell derived lymphoma incidence
|
J:34193
|
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:103922
|
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:90941
|
Atmtm1Awb/Atmtm1Awb
(CByJ.129S6-Atmtm1Awb)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x A.129S6-Atmtm1Awb)F1 or (A.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb/J)
|
increased T cell derived lymphoma incidence
|
J:226414
|
Atmtm1Awb/Atmtm1Awb Rad52tm1Aps/Rad52tm1Aps
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:90941
|
Atmtm1Bal/Atmtm1Bal
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:35914
|
Atmtm1Fwa/Atmtm1Fwa
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:61201
|
Atmtm1Led/Atmtm1Led
(involves: 129S6/SvEvTac * Black Swiss)
|
increased T cell derived lymphoma incidence
|
J:69726
|
Atmtm1Mfl/Atm+
(involves: 129T2/SvEms * C57BL/6J)
|
increased ovary tumor incidence
|
J:78527
|
Atmtm1Mfl/Atmtm1Mfl
(involves: 129T2/SvEms * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:69726
|
Atmtm2.1Fwa/Atmtm2.1Fwa Tg(VAV1-cre)1Graf/0
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:277750
|
B2mtm1Unc/B2mtm1Unc Prkdcscid/Prkdcscid
(NOD.Cg-B2mtm1Unc Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:102141
|
Bap1em1Test/Bap1+
(involves: FVB)
|
increased granulosa cell tumor incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
increased ovary tumor incidence
|
J:231692
|
Bap1em2Test/Bap1+
(involves: FVB)
|
increased granulosa cell tumor incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
increased ovary tumor incidence
|
J:231692
|
increased pancreatic islet cell carcinoma incidence
|
J:231692
|
Bap1em3Test/Bap1+
(involves: FVB)
|
increased granulosa cell tumor incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
increased ovary tumor incidence
|
J:231692
|
Bard1tm1Thl/Bard1tm2Thl Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bard1tm2Thl/Bard1tm2Thl Brca1tm1Thl/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bard1tm2Thl/Bard1tm2Thl Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam Tg(Ins2-cre)25Mgn/0 Tg(RIP1-Tag)2Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:146436
|
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam Tg(RIP1-Tag)2Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:146436
|
Bcl2l11tm1.1Boui/Bcl2l11+ Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased T cell derived lymphoma incidence
|
J:186117
|
Becn1tm1Blev/Becn1+
(involves: 129X1/SvJ * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:86953
|
Bhlha15tm2(Kras)Skz/Bhlha15+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased pancreas adenoma incidence
|
J:105076
|
increased pancreatic acinar cell carcinoma incidence
|
J:105076
|
Bin1tm1Gcp/Bin1tm2Gcp Tg(MMTV-Myc)141-3Led/0 Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:117330
|
Bin1tm1Gcp/Bin1tm2Gcp Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased granulosa cell tumor incidence
|
J:117330
|
increased mammary gland tumor incidence
|
J:117330
|
Bin1tm2Gcp/Bin1+ Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:117330
|
Blmtm1Ches/Blmtm4Ches Tg(Hsp70-1-cre)6Arge/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:112115
|
Blmtm1Ches/Blmtm4Ches Tg(KLK3-cre)1Ches/0
(involves: 129S6/SvEvTac)
|
increased mammary gland tumor incidence
|
J:112115
|
Blmtm1Ches/Blmtm4Ches Tg(LGB-cre)74Acl/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:112115
|
Bmftm1.1Ast/Bmftm1.1Ast
(B6.Cg-Bmftm1.1Anst)
|
increased T cell derived lymphoma incidence
|
J:133084
|
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr Ctnnb1tm1Mmt/Ctnnb1+ Krt14tm1.1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * 129X1/SvJ)
|
increased salivary gland tumor incidence
|
J:199091
|
Braftm1Bbd/Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)
|
increased gland tumor incidence
|
J:170095
|
increased pheochromocytoma incidence
|
J:170095
|
Braftm1Cpri/Braftm1Cpri Gnastm3Lsw/Gnastm3Lsw Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/NCr)
|
increased thyroid tumor incidence
|
J:168249
|
Braftm1Cpri/Braftm1Cpri Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:168249
|
increased thyroid tumor incidence
|
J:168249
|
Braftm1Cpri/Braftm1Cpri Tshrtm1Rmar/Tshrtm1Rmar Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB/NCr)
|
increased thyroid tumor incidence
|
J:168249
|
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Tg(Tg-cre/ERT2)#Mmcm/0
(involves: 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:172205
|
Braftm1Mmcm/Braf+ Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Tg(TPO-cre/ERT2)1139Tyj/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Trp53tm1Brn/Trp53tm3.1Tyj Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Trp53tm3.1Tyj/Trp53+ Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braftm1Mmcm Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+ Ptentm1Hwu/Pten+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:191327
|
increased prostate gland tumor incidence
|
J:191327
|
increased prostate intraepithelial neoplasia incidence
|
J:191327
|
Brca1tm1Aash/Brca1tm1Aash Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:119996
|
increased salivary adenocarcinoma incidence
|
J:119996
|
Brca1tm1Aash/Brca1tm1Aash Trp53tm1Brd/Trp53+ Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)
|
increased mammary gland ductal carcinoma incidence
|
J:119996
|
increased mammary gland tumor incidence
|
J:119996
|
increased salivary adenocarcinoma incidence
|
J:119996
|
Brca1tm1Arge/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129S/SvEv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Brca1tm1Bhk/Brca1+
(C.129P2-Brca1tm1Bhk)
|
increased mammary gland tumor incidence
|
J:198018
|
Brca1tm1Bhk/Brca1+ Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi Brca1tm1Bhk)
|
increased mammary adenocarcinoma incidence
|
J:198018
|
increased mammary gland tumor incidence
|
J:198018
|
Brca1tm1Brn/Brca1+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Brca1tm1Brn/Brca1tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased ovarian carcinoma incidence
|
J:189304
|
increased ovary tumor incidence
|
J:189304
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased mammary gland tumor incidence
|
J:178595
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * Black Swiss * FVB)
|
increased mammary adenocarcinoma incidence
|
J:54533
|
increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * Black Swiss)
|
increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Cxd/Brca1tm2Cxd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB)
|
increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Thl/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased mammary gland tumor incidence
|
J:70271
|
increased T cell derived lymphoma incidence
|
J:81541
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:81541
|
Brca1tm2Arge/Brca1tm2Arge
(129-Brca1tm2Arge)
|
increased mammary gland tumor incidence
|
J:69187
|
Brca1tm2Arge/Brca1tm2Arge
(involves: 129/Sv * C57BL/6J * MF1)
|
increased mammary gland tumor incidence
|
J:69187
|
Brca1tm2Cxd/Brca1tm2Cxd Pkmtm1.1Mgvh/Pkmtm1.1Mgvh Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * 129S7/SvEvBrd * FVB/N)
|
increased mammary gland tumor incidence
|
J:205213
|
Brca1tm2Cxd/Brca1tm2Cxd Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd Tg(MMTV-cre)4Mam/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Esr1)#Paf/0 Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
Brca1tm2Mak/Brca1tm2Mak Chek2tm1Mak/Chek2tm1Mak Tg(Lck-cre)548Jxm/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Chek2tm1Mak/Chek2tm1Mak Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Tg(Lck-cre)548Jxm/? Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary gland tumor incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Trp53tm1Brd/Trp53+ Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:90512
|
Brca1tm3Cxd/Brca1tm3Cxd
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary gland tumor incidence
|
J:94114
|
Brca1tm4Cxd/Brca1tm4Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss)
|
increased mammary gland ductal carcinoma incidence
|
J:112308
|
increased mammary gland tumor incidence
|
J:112308
|
Brca1tm5.1Cxd/Brca1tm5.1Cxd
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary gland tumor incidence
|
J:155810
|
increased T cell derived lymphoma incidence
|
J:155810
|
Brca2tm1Arge/Brca2tm2Arge Waptm1(cre)Arge/Wap+
(involves: 129S/SvEv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:70564
|
Brca2tm1Brn/Brca2+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
increased mammary gland tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Brca2tm1Brn/Brca2tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
increased mammary gland tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53+ Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
increased mammary gland tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Cam Krastm4Tyj/Kras+ Trp53tm3Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic acinar cell carcinoma incidence
|
J:166678
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2+ Krastm4Tyj/Kras+ Trp53tm3Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Brn Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Cam
(involves: 129S/SvEv * MF1)
|
increased T cell derived lymphoma incidence
|
J:46812
|
Brca2tm1Cbl/Brca2tm1Cbl
(either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2))
|
increased T cell derived lymphoma incidence
|
J:44386
|
Brca2tm1Kamc/Brca2tm1Kamc Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)
|
increased mammary gland tumor incidence
|
J:109193
|
Brca2tm1Mbn/Brca2+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased mammary gland tumor incidence
|
J:67445
|
Brca2tm2Arge/Brca2tm2Arge Waptm1(cre)Arge/Waptm1(cre)Arge
(involves: 129S1/Sv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:70564
|
Brf1tm1Arte/Brf1tm1Arte Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Brip1Gt(RRI409)Byg/Brip1Gt(RRI409)Byg
(involves: 129P2/OlaHsd)
|
increased Harderian gland adenoma incidence
|
J:227115
|
increased pituitary adenoma incidence
|
J:227115
|
Calcatm1.1(cre/ERT2)Ptch/Calca+ Trp53tm1Brn/Trp53tm1Brn Rb1tm2Brn/Rb1tm2Brn
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased thyroid tumor incidence
|
J:190366
|
Calcatm1.1(cre/ERT2)Ptch/Calca+ Trp53tm1Brn/Trp53tm1Brn Rb1tm2Brn/Rb1tm2Brn Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N)
|
increased thyroid tumor incidence
|
J:190366
|
Cav1tm1Mls/Cav1+ Tg(MMTV-PyVT)634Mul/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:132472
|
Cav1tm1Mls/Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:147439
|
Cav1tm1Mls/Cav1tm1Mls Tg(MMTV-PyVT)634Mul/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:132472
|
Ccdc80tm1Ppal/Ccdc80tm1Ppal
(Not Specified)
|
increased ovarian carcinoma incidence
|
J:217742
|
increased thyroid adenoma incidence
|
J:217742
|
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam)
|
increased mammary adenocarcinoma incidence
|
J:241259
|
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam/0 Tg(MMTV-PyVT)634Mul/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:241259
|
Ccnctm1.1Pisc/Ccnctm1.1Pisc Tg(Lck-LMO1)11Sjk/0 Tg(Mx1-cre)1Cgn/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:217695
|
Ccnd1tm1Dsn/Ccnd1tm1Dsn Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129 * C57BL/6)
|
increased pituitary adenoma incidence
|
J:66707
|
Ccnd1tm1Wbg/Ccnd1+ Tg(MMTVneu)202Mul/0 Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1+ Tg(MMTVneu)202Mul/0 Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1tm1Wbg Tg(MMTVneu)202Mul/0 Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1tm1Wbg Tg(MMTVneu)202Mul/0 Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm4Pisc/Ccnd1tm4Pisc Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:156591
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:88120
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased T cell derived lymphoma incidence
|
J:88120
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+ Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd)
|
increased T cell derived lymphoma incidence
|
J:160931
|
Cd28tm1Mak/Cd28tm1Mak Rc3h1san/Rc3h1+
(involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu)
|
increased T cell derived lymphoma incidence
|
J:189087
|
Cdc73Gt(RRE190)Byg/Cdc73+
(B6.129P2-Cdc73Gt(RRE190)Byg)
|
increased parathyroid adenoma incidence
|
J:243366
|
increased parathyroid gland tumor incidence
|
J:243366
|
Cdc73tm1Btt/Cdc73+ Tg(PTH-cre)4167Slib/0
(Not Specified)
|
increased parathyroid adenoma incidence
|
J:243366
|
increased parathyroid gland tumor incidence
|
J:243366
|
Cdc73tm1Btt/Cdc73tm1Btt Tg(PTH-cre)4167Slib/0
(Not Specified)
|
increased parathyroid adenoma incidence
|
J:243366
|
increased parathyroid gland tumor incidence
|
J:243366
|
Cdh1tm1Jjon/Cdh1+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1+ Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:171765
|
increased mammary gland tumor incidence
|
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53+ Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary gland tumor incidence
|
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary gland tumor incidence
|
J:171765
|
Cdh1tm2Kem/Cdh1+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)7Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:212549
|
Cdh13tm1Brns/Cdh13tm1Brns Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:132759
|
Cdk4tm1.1Bbd/Cdk4+ Krastm1Bbd/Kras+ Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
|
increased pituitary adenoma incidence
|
J:86101
|
Cdk5rap2an/Cdk5rap2an
(Not Specified)
|
increased ovary adenoma incidence
|
J:15165
|
Cdk6tm1Phin/Cdk6+ Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:144975
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased Leydig cell tumor incidence
|
J:70894
|
increased sebaceous gland adenoma incidence
|
J:70894
|
increased T cell derived lymphoma incidence
|
J:70894
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Tg(MMTV-vHaras)SH1Led/0
(involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:66183
|
increased salivary adenocarcinoma incidence
|
J:66183
|
Cdkn1btm1Ako/Cdkn1b+ KitW-v/KitW-v
(involves: 129S1/Sv * C57BL/6J)
|
increased ovary adenoma incidence
|
J:236161
|
increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1b+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp)
|
increased thyroid adenoma incidence
|
J:165293
|
increased thyroid carcinoma incidence
|
J:165293
|
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:50053
|
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv)
|
increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1btm1Ako Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:50053
|
Cdkn1btm1Ako/Cdkn1btm1Ako KitW-v/KitW-v
(involves: 129S1/Sv * C57BL/6J)
|
increased ovary adenoma incidence
|
J:236161
|
increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1btm1Ako Men1tm1.1Ctre/Men1+
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:120835
|
increased pancreas tumor incidence
|
J:120835
|
increased parathyroid gland tumor incidence
|
J:120835
|
increased pituitary gland tumor incidence
|
J:120835
|
increased testis tumor incidence
|
J:120835
|
increased thyroid tumor incidence
|
J:120835
|
Cdkn1btm1Kin/Cdkn1btm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary adenoma incidence
|
J:33402
|
Cdkn1btm1Mlf/Cdkn1b+ Crebbptm1Jvd/Crebbptm1Jvd Tg(MMTV-cre)4Mam/0
(involves: 129 * C57BL/6 * CBA * FVB)
|
increased T cell derived lymphoma incidence
|
J:88323
|
Cdkn1btm1Mlf/Cdkn1b+ Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor * C57BL/6J)
|
increased pituitary adenoma incidence
|
J:33400
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Nkx3-1tm1.1Saa/Nkx3-1tm1.1Saa
(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:89571
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Trp53tm1Brd/Trp53tm1Brd
(involves: C3H * C57BL/6J * NIH)
|
increased T cell derived lymphoma incidence
|
J:87536
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Trp53tm1Brd/Trp53tm1Brd
(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:87536
|
Cdkn1btm2Mlf/Cdkn1btm2Mlf Tg(Pomc1-cre)1Mlf/0
(involves: 129S4/SvJaeSor)
|
increased pituitary gland tumor incidence
|
J:107588
|
Cdkn1btm3Mlf/Cdkn1btm3Mlf
(involves: 129S4/SvJaeSor)
|
increased pituitary gland tumor incidence
|
J:107588
|
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N)
|
increased pancreas adenoma incidence
|
J:198619
|
increased pancreas tumor incidence
|
J:198619
|
increased pancreatic intraepithelial neoplasia incidence
|
J:198619
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:44427
|
Cdkn2atm1Rdp/Cdkn2a+ Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0 Tg(Pdx1-cre)6Tuv/0 Tg(tetO-MYC)36Bop/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
|
increased pancreas tumor incidence
|
J:197052
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197052
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(tetO-BRAF*V600E)29Lc/0 Tg(Tyr-rtTA)37Lc/0
(involves: 129/Sv * C57BL/6J * SJL)
|
increased prostate gland adenocarcinoma incidence
|
J:144358
|
Cdkn2atm2.1Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased pancreas adenoma incidence
|
J:198619
|
increased pancreas tumor incidence
|
J:198619
|
increased pancreatic intraepithelial neoplasia incidence
|
J:198619
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298,
J:87196
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:108298,
J:87196
|
increased pancreatic intraepithelial neoplasia incidence
|
J:87196
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:187012
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Krastm4Tyj Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:151781
|
Cdkn2btm1Bbd/Cdkn2btm1Bbd Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased pituitary adenoma incidence
|
J:63299
|
increased testis tumor incidence
|
J:63299
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased pheochromocytoma incidence
|
J:63299
|
increased pituitary adenoma incidence
|
J:63299
|
increased T cell derived lymphoma incidence
|
J:63299
|
increased testis tumor incidence
|
J:63299
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Cdkn2dtm1Maro/Cdkn2dtm1Maro
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
|
increased pheochromocytoma incidence
|
J:68829
|
increased pituitary adenoma incidence
|
J:68829
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:50053
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi)
|
increased mammary gland tumor incidence
|
J:198018
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi Men1tm1.1Ctre/Men1+
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:120835
|
increased Leydig cell tumor incidence
|
J:120835
|
increased pancreas tumor incidence
|
J:120835
|
increased parathyroid gland tumor incidence
|
J:120835
|
increased testis tumor incidence
|
J:120835
|
increased thyroid tumor incidence
|
J:120835
|
Chd2Gt(RRBO46)Byg/Chd2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:146176
|
Chek1tm1Sje/Chek1+ Tg(Wnt1)1Hev/0
(Not Specified)
|
increased mammary adenocarcinoma incidence
|
J:62919
|
Chek1tm2.1Sje/Chek1+ Trp53tm1Brn/Trp53+ Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary adenocarcinoma incidence
|
J:162126
|
increased mammary gland tumor incidence
|
J:162126
|
Chek1tm2.1Sje/Chek1+ Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary gland tumor incidence
|
J:162126
|
Chek1tm2.1Sje/Chek1tm2.1Sje Trp53tm1Brn/Trp53+ Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary gland tumor incidence
|
J:162126
|
Col1a1tm1(CAG-Mir22)Ppp/Col1a1tm1(CAG-Mir22)Ppp Tg(Mx1-cre)1Cgn/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:199366
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+ Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:222916
|
increased prostate gland tumor incidence
|
J:222916
|
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:171191
|
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:171191
|
Cop1Gt(XR0653)1.1Wtsi/Cop1Gt(XR0653)1.1Wtsi
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:178271
|
increased testicular teratoma incidence
|
J:178271
|
Cop1tm2.1Vmd/Cop1+ Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
|
increased prostate gland adenocarcinoma incidence
|
J:172653
|
increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Cop1tm2.1Vmd/Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb/0
(B6N.Cg-Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb)
|
increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Crebbptm1Jvd/Crebbptm1Jvd Tg(Lck-cre)548Jxm/0
(involves: 129 * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:105505
|
Crebbptm1Jvd/Crebbptm1Jvd Tg(MMTV-cre)4Mam/0
(involves: 129 * C57BL/6 * FVB)
|
increased T cell derived lymphoma incidence
|
J:88323
|
Csf2tm1Dran/Csf2tm1Dran Ifngtm1Ts/Ifngtm1Ts Il3tm1Glli/Il3tm1Glli
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:83086
|
Csf2tm1Mlg/Csf2tm1Mlg Ifngtm1Ts/Ifngtm1Ts Il3tm1Glli/Il3tm1Glli
(B6.129S-Csf2tm1Mlg Il3tm1Glli Ifngtm1TsIfngtm1Ts)
|
increased pituitary adenoma incidence
|
J:145518
|
Ctnnb1tm1Mmt/Ctnnb1+ Igs2tm1(CAG-Met)Zsu/Igs2+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:284956
|
increased prostate intraepithelial neoplasia incidence
|
J:284956
|
Ctnnb1tm1Mmt/Ctnnb1+ Krastm1Bbd/Kras+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:143034
|
Ctnnb1tm1Mmt/Ctnnb1+ Krastm4Tyj/Kras+ Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased testis tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+ Krastm4Tyj/Kras+ Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+ Ptentm1Hwu/Ptentm1Hwu Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+ Sox2tm1.1(cre/ERT2)Jpmb/Sox2+
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:201265
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(CYP19A1-cre)1Jri/0
(involves: 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Pbsn-cre)4Prb/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:143034,
J:284956
|
increased prostate intraepithelial neoplasia incidence
|
J:143034,
J:284956
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Wap-cre)11738Mam/0
(FVB.Cg-Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam)
|
increased mammary gland tumor incidence in breeding females
|
J:206839
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Wap-cre)11738Mam/0 Tg(Wap-Hgf)402Mig/0
(FVB.Cg-Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam Tg(Wap-Hgf)402Mig)
|
increased mammary gland tumor incidence in breeding females
|
J:206839
|
increased mammary gland tumor incidence in virgin females
|
J:206839
|
Ctsbtm1Jde/Ctsbtm1Jde Ctsztm1Thre/Ctsztm1Thre Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsztm1Thre Ctsbtm1Jde Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:157541
|
Ctsbtm1Jde/Ctsbtm1Jde Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsbtm1Jde Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:157541
|
Ctsztm1Thre/Ctsztm1Thre Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsztm1Thre Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:157541
|
Cul9tm1.2Yxi/Cul9+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:170976
|
increased pituitary gland tumor incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased ovary tumor incidence
|
J:170976
|
increased pituitary gland tumor incidence
|
J:170976
|
Dcctm1Nki/Dcctm1Nki Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:181090
|
Dclre1atm1Rleg/Dclre1atm1Rleg
(involves: 129S7/SvEvBrd)
|
increased ovarian teratoma incidence
|
J:102381
|
Dclre1atm1Rleg/Dclre1atm1Rleg Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:102381
|
Dcntm1Ioz/Dcn+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53511
|
Dcntm1Ioz/Dcntm1Ioz Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53511
|
Ddr2tm1a(EUCOMM)Wtsi/Ddr2tm1a(EUCOMM)Wtsi Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1b(EUCOMM)Wtsi/Ddr2tm1b(EUCOMM)Wtsi Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1c(EUCOMM)Wtsi/Ddr2tm1c(EUCOMM)Wtsi Tg(KRT14-cre)1Amc/0 Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * C57BL/6N * CBA * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1c(EUCOMM)Wtsi/Ddr2tm1c(EUCOMM)Wtsi Tg(MMTV-cre)#Mam/0 Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Del(16Tmprss2-Erg)1Sho/Del(16Tmprss2-Erg)1Sho Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Dicer1tm1Tara/Dicer1tm1Tara Ptentm1Hwu/Ptentm1Hwu Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased ovarian carcinoma incidence
|
J:182161
|
Dicer1tm1Tara/Dicer1tm1Tara Ptentm1Hwu/Ptentm1Hwu Trp53tm2Tyj/Trp53+ Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased ovarian carcinoma incidence
|
J:222579
|
Diras2em1Gpt/Diras2em1Gpt Krastm4Tyj/Kras+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * C57BL/6J * C57BL/6JGpt)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:348744
|
Diras2em1Gpt/Diras2em1Gpt Krastm4Tyj/Kras+ Ptf1atm1(cre)Hnak/Ptf1a+ Ube2ftm1c(EUCOMM)Hmgu/Ube2ftm1c(EUCOMM)Hmgu
(involves: 129S4/SvJae * C57BL/6)
|
increased pancreas tumor incidence
|
J:348744
|
Dkc1tm1Ppp/Y
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:81054
|
increased pheochromocytoma incidence
|
J:81054
|
Dmq1FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Dmq2FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Dmtf1tm1Cjs/Dmtf1+ Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1+ Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased ovary tumor incidence
|
J:126002
|
increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:126002
|
Dnd1Ter/?
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:29502
|
Dnd1Ter/Dnd1+
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1+
(involves: 129S1/Sv * C57BL/6)
|
increased testicular teratoma incidence
|
J:7954
|
increased testis tumor incidence
|
J:7954
|
Dnd1Ter/Dnd1+
(involves: 129P3/J)
|
increased testis tumor incidence
|
J:221231
|
Dnd1Ter/Dnd1Ter
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1Ter
(involves: 129S1/Sv * C57BL/6)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1Ter Sf1Gt(XD130)Byg/Sf1+
(involves: 129P2/OlaHsd * 129S1/SvImJ * 129T1/Sv)
|
increased testis tumor incidence
|
J:164224
|
Dock1tm2.1Jfco/Dock1+ Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ)
|
increased mammary adenocarcinoma incidence
|
J:196659
|
increased mammary gland tumor incidence
|
J:196659
|
Dock1tm2.1Jfco/Dock1tm2.1Jfco Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ)
|
increased mammary adenocarcinoma incidence
|
J:196659
|
increased mammary gland tumor incidence
|
J:196659
|
Drd2tm1Ebo/Drd2tm1Ebo
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary adenoma incidence
|
J:41857
|
E2f1tm1Meg/E2f1tm1Meg
(either: (involves: 129/Sv * 129S4/SvJae) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))
|
increased T cell derived lymphoma incidence
|
J:33100
|
E2f1tm1Njd/E2f1+ Rb1tm1Tyj/Rb1+
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
|
increased thyroid adenoma incidence
|
J:47108
|
E2f1tm1Njd/E2f1tm1Njd Rb1tm1Tyj/Rb1+
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
|
increased pituitary gland tumor incidence
|
J:47108
|
increased thyroid adenoma incidence
|
J:47108
|
E2f4tm1Lees/E2f4+ Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:81082
|
increased thyroid tumor incidence
|
J:81082
|
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow Eaf2tm1Zhow/Eaf2tm1Zhow Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb/0
(B6(Cg)-Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased prostate intraepithelial neoplasia incidence
|
J:145228
|
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Eef1a1tm1(Kras*)Arge/Eef1a1+ Igf1rtm2Arge/Igf1r+ Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+ Igf1rtm2Arge/Igf1rtm2Arge Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+ Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:146290
|
increased mammary gland tumor incidence
|
J:146290
|
Egr1tm1Jmi/Egr1tm1Jmi
(involves: 129 * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:123870
|
Elac2em1Afi/Elac2em1Afi Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * C57BL/6N)
|
increased prostate intraepithelial neoplasia incidence
|
J:336403
|
Emv30b/Emv30b Prkdcscid/Prkdcscid
(NOD.Cg-Emv30b Prkdcscid/Dvs)
|
increased T cell derived lymphoma incidence
|
J:29951
|
Epm2aTg(TcraK,TcrbK)TG-BFlv/Epm2a+
(involves: C57BL/6 * C57BL/10 * C57BR/cd * CBA/J)
|
increased T cell derived lymphoma incidence
|
J:112696
|
Erbb2tm8(Erbb2)Mul/Erbb2+ Ptentm1Hwu/Pten+ Tg(MMTV-cre)7Mul/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133305
|
Erbb2tm8(Erbb2)Mul/Erbb2+ Ptentm1Hwu/Ptentm1Hwu Tg(MMTV-cre)7Mul/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133305
|
Erbb2tm8(Erbb2)Mul/Erbb2+ Tg(MMTV-cre)7Mul/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:89255
|
Erbb3tm1.1(ERBB3)Mul/Erbb3+ Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:189292
|
Erbb3tm1.1(ERBB3)Mul/Erbb3tm1.1(ERBB3)Mul Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:189292
|
Ergtm1.1Sho/Ergtm1.1Sho Ptentm1Hwu/Ptentm1Hwu Tmprss2tm3Sho/Tmprss2tm3Sho Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:212219
|
Esr1tm1Ksk/Esr1tm1Ksk Esr2tm1Unc/Esr2tm1Unc Inhatm1Bay/Inha+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk Esr2tm1Unc/Esr2tm1Unc Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
increased testis tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
increased testis tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased mammary gland tumor incidence
|
J:76653
|
Esr1tm1Ksk/Esr1tm1Ksk Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:54215
|
Esr2tm1Unc/Esr2tm1Unc Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
increased testis tumor incidence
|
J:84989
|
Ets2tm1Rgo/Ets2tm5.1Rgo Ptentm1.1Mwst/Ptentm1.1Mwst Tg(S100a4-cre)1Gle/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:153747
|
Ets2tm3Rgo/Ets2+ Meox2tm1(cre)Sor/? Tg(MMTV-cre)7Mul/?
(involves: 129S4/SvJaeSor * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2+ Meox2tm1(cre)Sor/? Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2tm3.1Rgo Meox2tm1(cre)Sor/? Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2tm3Rgo Meox2tm1(cre)Sor/? Tg(MMTV-cre)7Mul/?
(involves: 129S4/SvJaeSor * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Etv4tm1Hass/Etv4tm1Hass Tg(MMTVneu)202Mul/Tg(MMTVneu)202Mul
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:87017
|
Etv6tm3(NTRK3)Sho/Etv6+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:130323
|
Etv6tm3(NTRK3)Sho/Etv6+ Tg(Wap-cre)11738Mam/0
(involves: 129S1/Sv * C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:130323
|
Ewsr1tm1(ERG)Thr/Ewsr1+ Rag1tm1(cre)Thr/Rag1+
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:98679
|
F2rtm1Pago/F2rtm1Pago Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rtm1Pago Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:138924
|
F2rl1tm1Bpd/F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:138924
|
Fancftm1Nki/Fancftm1Nki
(involves: 129P2/OlaHsd * FVB)
|
increased granulosa cell tumor incidence
|
J:180025
|
increased ovary tumor incidence
|
J:180025
|
Fbxo4tm1.1Jadi/Fbxo4+
(Not Specified)
|
increased mammary gland tumor incidence
|
J:178645
|
Fbxo4tm1.1Jadi/Fbxo4tm1.1Jadi
(Not Specified)
|
increased mammary gland tumor incidence
|
J:178645
|
Fbxw7tm1Iaai/Fbxw7tm1Iaai Tg(Lck-cre)1Cwi/0
(involves: 129/Sv * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:137138
|
Fbxw7tm1Kei/Fbxw7tm1Kei Trp53tm1Tyj/Trp53tm1Tyj Tg(Lck-cre)1Cwi/?
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:128523
|
Fdxrtm1Xch/Fdxr+
(B6.Cg-Fdxrtm1Xch)
|
increased T cell derived lymphoma incidence
|
J:244082
|
Fen1tm2.1Bhsh/Fen1tm2.1Bhsh
(involves: 129S1/Sv)
|
increased thymus tumor incidence
|
J:218627
|
Fgfr4tm1Axul/Fgfr4+ Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul Tg(WapTgfa)215Bri/0
(FVB.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Flot2tm1Mak/Flot2tm1Mak Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:203238
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp Foxo3tm1Rdp/Foxo3tm1.1Rdp Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp Foxo3tm1Rdp/Foxo3tm1.1Rdp Ptentm1Hwu/Ptentm1Hwu Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp Foxo3tm1Rdp/Foxo3tm1.1Rdp Tg(CYP19A1-cre)1Jri/0
(involves: 129S6/SvEvTac)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1Rdp Foxo3tm1Rdp/Foxo3tm1Rdp Foxo4tm1Rdp/Foxo4tm1Rdp Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:118179
|
Foxo3mommeR1/Foxo3mommeR1 Tg(HBA1-GFP)1Ew/Tg(HBA1-GFP)1Ew
(FVB/NJ-Foxo3mommeR1 Tg(HBA1-Gfp)1Ew)
|
increased ovarian teratoma incidence
|
J:170710
|
Foxo3tm1.1Rdp/Foxo3+ Foxo4tm1.1Rdp/Foxo4tm1.1Rdp
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N)
|
increased Harderian gland tumor incidence
|
J:118179
|
increased ovary tumor incidence
|
J:118179
|
increased pituitary adenoma incidence
|
J:118179
|
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased ovary tumor incidence
|
J:118179
|
increased prolactinoma incidence
|
J:118179
|
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp Foxo4tm1.1Rdp/Foxo4tm1.1Rdp
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N)
|
increased Harderian gland tumor incidence
|
J:118179
|
increased ovarian teratoma incidence
|
J:118179
|
increased ovary tumor incidence
|
J:118179
|
increased pituitary adenoma incidence
|
J:118179
|
Fshrtm1Saco/Fshr+
(involves: 129)
|
increased ovary tumor incidence
|
J:140008
|
Fshrtm1Saco/Fshrtm1Saco
(involves: 129)
|
increased ovarian carcinoma incidence
|
J:70933
|
Fzr1tm1.1Mama/Fzr1+
(involves: BALB/cJ * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:137456
|
increased mammary gland tumor incidence
|
J:137456
|
increased testis tumor incidence
|
J:137456
|
Gcgrtm1Jcp/Gcgrtm1Jcp
(DBA/1LacJ-Gcgrtm1Jcp)
|
increased glucagonoma incidence
|
J:176507
|
increased pancreas tumor incidence
|
J:176507
|
Gct1SJL/Bm/Gct1SWR/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct1SWR/Bm/Gct1SWR/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct4SJL/Bm/?
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct4SJL/Bm/Gct4SJL/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:87114
|
Gct4SJL/Bm/Gct4SJL/Bm Gct6SJL/Gct6SJL
(involves: CAST/Ei * SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:87114
|
Gct5SWXJ9/BmJ/Gct5SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct7SWXJ9/BmJ/Gct7SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct8SWXJ9/BmJ/Gct8SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct9SWXJ9/BmJ/Gct9SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gon4ljusty/Gon4ljusty
(C3HeB/FeJ-Gon4ljusty)
|
increased salivary adenocarcinoma incidence
|
J:197352
|
Gpx7tm1Whle/Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:193993
|
increased salivary gland tumor incidence
|
J:193993
|
Grb2tm1Paw/Grb2+ Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:93530
|
Grb2tm1Paw/Grb2+ Ptentm2Mak/Ptentm2Mak Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:93530
|
Grb2tm1Paw/Grb2+ Tg(MMTV-PyVT)634Mul/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:51424
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sor+ Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:234601
|
increased prostate intraepithelial neoplasia incidence
|
J:234601
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sortm1(CAG-AR)Zsu Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:234601
|
increased prostate intraepithelial neoplasia incidence
|
J:234601
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Ptentm1Mro/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:184533
|
increased prostate intraepithelial neoplasia incidence
|
J:184533
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Rb1tm2Brn/Rb1tm2Brn Tg(Gfap-cre)2Brn/0
(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased pituitary gland tumor incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Gfap-cre)2Brn/0
(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased pituitary gland tumor incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Tg(Gfap-cre)2Brn/0
(either: (involves: 129P2/OlaHsd * FVB/N) or (involves: 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased mammary gland tumor incidence
|
J:187257
|
increased pituitary gland tumor incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:184533
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Rb1tm2Brn/Rb1+ Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Rb1tm2Brn/Rb1tm2Brn Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+ Tg(MMTV-cre)7Mul/0
(involves: BALB/c * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:173655
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+ Tg(Wap-cre)1Gsc/0
(involves: BALB/c * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:173655
|
increased mammary gland tumor incidence
|
J:173655
|
Gt(ROSA)26Sortm1(CAG-PTPN1,-EGFP)Mtr/Gt(ROSA)26Sor+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:231906
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+ Tacc3tm1.1Tno/Tacc3+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+ Tacc3tm1.1Tno/Tacc3tm1.2Tno Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)
|
increased prostate gland tumor incidence
|
J:130367
|
increased prostate intraepithelial neoplasia incidence
|
J:130367
|
increased T cell derived lymphoma incidence
|
J:130367
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:280854
|
increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0 Trp53tm1Brn/Trp53+
(involves: 129 * C57BL/6 * CBA)
|
increased pancreas tumor incidence
|
J:289183
|
increased pancreatic ductal adenocarcinoma incidence
|
J:289183
|
increased pancreatic intraepithelial neoplasia incidence
|
J:289183
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+ Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac)
|
increased thyroid adenoma incidence
|
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:170965
|
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+ Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:160931
|
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:238768
|
increased prostate intraepithelial neoplasia incidence
|
J:238768
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+ Krastm4Tyj/Krastm4Tyj Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae * 129S4/SvJaeSor)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+ Krastm4Tyj/Krastm4Tyj Tg(Pdx1-cre/Esr1*)35.10Dam/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu/Gt(ROSA)26Sor+ Tg(Lck-cre)548Jxm/0
(B6.Cg-Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu Tg(Lck-cre)548Jxm)
|
increased T cell derived lymphoma incidence
|
J:185287
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Tg(MMTV-cre)1Mam/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary gland tumor incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Tg(MMTV-cre)#Tfln/0
(involves: 129S6/SvEvTac)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
increased mammary gland tumor incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Tg(MMTV-cre)#Tfln/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
increased mammary gland tumor incidence
|
J:170898
|
increased T cell derived lymphoma incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased mammary gland tumor incidence
|
J:170898
|
increased T cell derived lymphoma incidence
|
J:170898
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras2)12Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased pancreas tumor incidence
|
J:184378
|
increased pancreatic intraepithelial neoplasia incidence
|
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras2)12Hev/0 Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:184378
|
increased pancreatic intraepithelial neoplasia incidence
|
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
increased pancreatic intraepithelial neoplasia incidence
|
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6057Njen/0
(involves: C3H * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: C3H * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6113Njen/0
(involves: C3H * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc3)12740Njen/0
(involves: C3H * C57BL/6J)
|
increased pheochromocytoma incidence
|
J:153656
|
increased T cell derived lymphoma incidence
|
J:153656
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:239660
|
increased prostate intraepithelial neoplasia incidence
|
J:239660
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:239660
|
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:200002
|
increased prostate intraepithelial neoplasia incidence
|
J:200002
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:140423
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:140423
|
increased pancreatic intraepithelial neoplasia incidence
|
J:140423
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ Ptentm2Mak/Ptentm2Mak Tg(RasE)290Biat/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:226601
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ Tg(RasE)290Biat/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:226601
|
increased pancreatic ductal adenocarcinoma incidence
|
J:226601
|
increased pancreatic intraepithelial neoplasia incidence
|
J:226601
|
increased sebaceous gland tumor incidence
|
J:226601
|
Gt(ROSA)26Sortm2(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:170965
|
Gt(ROSA)26Sortm2(myc*T58A)Rcse/Gt(ROSA)26Sortm2(myc*T58A)Rcse Tg(Wap-cre)11738Mam/0
(involves: 129 * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:169403
|
increased pituitary gland tumor incidence
|
J:169403
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
increased pancreatic intraepithelial neoplasia incidence
|
J:197054
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+ Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S6/SvEvTac)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:197054
|
Gt(ROSA)26Sortm2.1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * C57BL/6 * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:153656
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Hmga2tm1.1Mmw/Hmga2+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Prdm1tm1Clme/Prdm1tm1Clme Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
increased pancreatic intraepithelial neoplasia incidence
|
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
increased pancreatic intraepithelial neoplasia incidence
|
J:245611
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sor+ Tg(Tek-cre)1Ywa/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased T cell derived lymphoma incidence
|
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * CD-1 * SJL)
|
increased thymus tumor incidence
|
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai Tg(Tek-cre)1Ywa/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased T cell derived lymphoma incidence
|
J:263520
|
H2u/H2u Tg(TCRA)B1Jg/0
(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg/J)
|
increased T cell derived lymphoma incidence
|
J:92992
|
H2u/H2u Tg(TCRA)B1Jg/0 Tg(TCRB)C14Jg/0
(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg)
|
increased T cell derived lymphoma incidence
|
J:92992
|
H2axtm1Fwa/H2ax+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:84879
|
H2axtm1Fwa/H2axtm1Fwa
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:84879
|
H2axtm1Fwa/H2axtm1Fwa Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:84879
|
Hace1tm1Pngr/Hace1tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:125183
|
Hdac1tm1.1Shmc/Hdac1tm1.1Shmc Hdac2tm1.1Shmc/Hdac2tm1.1Shmc Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:194769
|
HelqGt(RRF112)Byg/Helq+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased Harderian gland tumor incidence
|
J:206104
|
increased pituitary adenoma incidence
|
J:206104
|
HelqGt(RRF112)Byg/HelqGt(RRF112)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gland tumor incidence
|
J:206104
|
increased granulosa cell tumor incidence
|
J:206104
|
increased Harderian gland tumor incidence
|
J:206104
|
increased mammary gland tumor incidence
|
J:206104
|
increased ovary tumor incidence
|
J:206104
|
increased pituitary adenoma incidence
|
J:206104
|
Hic1tm1Sbb/Hic1+
(involves: 129S4/SvJae * C57BL/6)
|
increased pancreatic islet cell carcinoma incidence
|
J:81448
|
Hip1tm4Tsr/Hip1+ Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:151974
|
Hmgn1tm1Mbus/Hmgn1tm1Mbus
(involves: 129X1/SvJ)
|
increased pheochromocytoma incidence
|
J:100773
|
Hprt1tm1(CAG-BRF1)Gu/Hprt1+ Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Hprt1tm1(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm1(CUX1)Anep)
|
increased mammary adenocarcinoma incidence
|
J:152682
|
increased mammary gland tumor incidence
|
J:152682
|
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Y Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:144357
|
increased prostate intraepithelial neoplasia incidence
|
J:144357
|
Hprt1tm2(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm2(CUX1)Anep)
|
increased mammary adenocarcinoma incidence
|
J:152682
|
increased mammary gland tumor incidence
|
J:152682
|
Hrastm1Jaf/Hrastm1Jaf Nf2tm2Gth/Nf2tm2Gth Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm1Jaf/Hrastm1Jaf Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm1Jaf/Hrastm1Jaf Trp53tm1Brn/Trp53tm1Brn Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm2Xbr/Hrastm2Xbr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:137729
|
Hspa5tm1Alee/Hspa5+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/?
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:142106
|
increased prostate intraepithelial neoplasia incidence
|
J:142106
|
Htatip2tm1Hx/Htatip2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased ovary tumor incidence
|
J:87066
|
Icostm1Flv/Icostm1Flv Rc3h1san/Rc3h1+
(involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu)
|
increased T cell derived lymphoma incidence
|
J:189087
|
Id1tm1Zhu/Id1tm1Zhu Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:44278
|
Id2tm1Yyk/Id2+ Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Id2tm1Yyk/Id2tm1Yyk Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Ifngtm1Ts/Ifngtm1Ts
(B6.129S7-Ifngtm1Ts)
|
increased T cell derived lymphoma incidence
|
J:77491
|
Igh-Vtm1(Igh-Vx24)Hmb/Igh-Vtm1(Igh-Vx24)Hmb
(involves: 129/Sv * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:54380
|
Ightm1(PAX5)Mbu/Igh+
(B6.Cg-Ightm1(PAX5)Mbu)
|
increased T cell derived lymphoma incidence
|
J:118111
|
Ightm1(PAX5)Mbu/Ightm1(PAX5)Mbu
(B6.Cg-Ightm1(PAX5)Mbu)
|
increased T cell derived lymphoma incidence
|
J:118111
|
Igs2tm1(CAG-Met)Zsu/Igs2+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:268934
|
increased prostate gland tumor incidence
|
J:268934
|
increased prostate intraepithelial neoplasia incidence
|
J:268934
|
Igs2tm1(CAG-Met)Zsu/Igs2+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:268934
|
Ikzf1plstc/Ikzf1+
(C57BL/6JSfdAnu-Ikzf1plstc)
|
increased T cell derived lymphoma incidence
|
J:84569
|
Ikzf1tm1(Pax5)Mbu/Ikzf1+ Tg(Lck-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:118111
|
Ikzf1tm1.1(Pax5)Mbu/Ikzf1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:118111
|
Ikzf1tm3.1Mbu/Ikzf1tm3.1Mbu Il7rtm1.1(icre)Hrr/Il7r+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased T cell derived lymphoma incidence
|
J:209928
|
Ikzf1tm3Kge/Ikzf1tm3Kge Tg(CD2-icre)4Kio/?
(involves: C57BL/10 * CBA/Ca)
|
increased T cell derived lymphoma incidence
|
J:209927
|
Ing2tm1.1Ccha/Ing2tm1.1Ccha
(involves: 129 * C57BL/6J * FVB/N)
|
increased Harderian gland adenoma incidence
|
J:167311
|
Inhatm1Bay/Inhatm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:125349,
J:20450
|
increased ovary tumor incidence
|
J:125349,
J:3315
|
increased testis tumor incidence
|
J:125349
|
Inhatm1Bay/Inhatm1Bay
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
increased testis tumor incidence
|
J:84989
|
Inhatm1Bay/Inhatm1Bay Smad3tm1Par/Smad3+
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/Sv * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:125349
|
increased ovary tumor incidence
|
J:125349
|
Inhatm1Bay/Inhatm1Bay Smad3tm1Par/Smad3tm1Par
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/Sv * C57BL/6)
|
increased ovary tumor incidence
|
J:125349
|
Ino80tm1.1Schg/Ino80+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:221224
|
Inpp5jtm1.1Cmit/Inpp5jtm1.1Cmit Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6)
|
increased mammary gland tumor incidence
|
J:224914
|
Kdm5atm1.1Kael/Kdm5a+ Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
increased thyroid tumor incidence
|
J:175625
|
Kdm5atm1.1Kael/Kdm5atm1.1Kael Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
increased thyroid tumor incidence
|
J:175625
|
Kdm5atm1Kael/Kdm5atm1Kael Men1tm2.1Mmey/Men1tm2.1Mmey Tg(Ins2-cre)23Herr/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N)
|
increased insulinoma incidence
|
J:175625
|
KitW-v/KitW-v Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased ovary tumor incidence
|
J:236161
|
KitlSl-J/Kitl+
(involves: 129)
|
increased testicular teratoma incidence
|
J:50508
|
KitlSl/Kitl+
(involves: 129/Sv * C3H)
|
increased testicular teratoma incidence
|
J:50508
|
Klrk1tm1Dhr/Klrk1tm1Dhr Tg(TRAMP)8247Ng/?
(involves: C57BL/6 * CD-1)
|
increased prostate gland tumor incidence
|
J:134509
|
Kmt2atm1Thr/Kmt2a+ Mllt3tm2Thr/Mllt3+ Tg(Lck-cre)1Thr/?
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:100794
|
Krastm1.1Khai/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:276349
|
Krastm1Bbd/Kras+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:143034
|
increased prostate intraepithelial neoplasia incidence
|
J:143034
|
Krastm1Bbd/Kras+ Trp53tm1Brd/Trp53+ Tg(Cela1-tTA)#Eps/? Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:119988
|
Krastm1Bbd/Krastm1Bbd Tg(Cela1-tTA)#Eps/? Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:119988
|
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm2Tyj/Kras+
(involves: 129S2/SvPas)
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm2Tyj/Kras+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm2Tyj/Kras+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm3Tyj/Kras+
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm3Tyj/Kras+ Mir21atm1.1Eno/Mir21atm1.1Eno
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:164198
|
Krastm3Tyj/Krastm3Tyj
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:237900
|
Krastm4Tyj/Kras+ Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+ Tg(Pdx1-cre)6Tuv/0 TgTn(sb-T2/Onc)#Dla/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased pancreas tumor incidence
|
J:186717
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186717
|
increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
Krastm4Tyj/Kras+ Krt19tm1(cre/ERT)Ggu/Krt19+ Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:254370
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:184935
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased pancreas tumor incidence
|
J:164210
|
increased pancreatic ductal adenocarcinoma incidence
|
J:164210
|
increased pancreatic intraepithelial neoplasia incidence
|
J:164210
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
|
increased ovary tumor incidence
|
J:161953
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:184935
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:164210
|
increased pancreatic intraepithelial neoplasia incidence
|
J:164210
|
Krastm4Tyj/Kras+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp)
|
increased thyroid carcinoma incidence
|
J:147732
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:87973
|
increased pancreatic intraepithelial neoplasia incidence
|
J:262746
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(B6.129(Cg)-Krastm4Tyj Ptf1atm1.1(cre)Cvw)
|
increased pancreas tumor incidence
|
J:138959
|
increased pancreatic ductal adenocarcinoma incidence
|
J:138959
|
increased pancreatic intraepithelial neoplasia incidence
|
J:138959
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(MUC1)79.24Gend/0
(B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw Tg(MUC1)79.24Gend)
|
increased pancreas tumor incidence
|
J:138959,
J:234412
|
increased pancreatic ductal adenocarcinoma incidence
|
J:138959
|
increased pancreatic intraepithelial neoplasia incidence
|
J:138959,
J:234412
|
Krastm4Tyj/Kras+ Raf1tm2Bacc/Raf1tm2Bacc Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Scribtm1.1Phum/Scrib+ Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:178461
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+ Scribtm1.1Phum/Scribtm1.1Phum Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:178461
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Krastm4Tyj/Kras+ Tg(CAG-Bgeo,-tsA58T)T26Ichi/0 Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:214846
|
increased pancreatic intraepithelial neoplasia incidence
|
J:214846
|
Krastm4Tyj/Kras+ Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased pancreas tumor incidence
|
J:197054
|
Krastm4Tyj/Kras+ Tg(Erbb2*)#Maed/0 Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:262746
|
Krastm4Tyj/Kras+ Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
|
increased lymphoblastic lymphoma incidence
|
J:88163
|
Krastm4Tyj/Kras+ Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/?
(involves: 129S4/SvJae * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:87973
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:276349,
J:214846,
J:98936
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:220300
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:276349
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Usp9xtm1Tuv/Y
(involves: 129S4/SvJae * FVB/N)
|
increased pancreas tumor incidence
|
J:186717
|
increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Usp9xtm1Tuv/Usp9x+
(involves: 129S4/SvJae * FVB/N)
|
increased pancreas tumor incidence
|
J:186717
|
increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:164210
|
increased pancreatic intraepithelial neoplasia incidence
|
J:87196,
J:164210
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
Krastm4Tyj/Kras+ Tgfbr2tm1.2Hlm/Tgfbr2+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:116129
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116129
|
increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+ Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:116129
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116129
|
increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm2Tyj Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:98936
|
increased pancreatic intraepithelial neoplasia incidence
|
J:98936
|
increased T cell derived lymphoma incidence
|
J:98936
|
Krastm4Tyj/Krastm4Tyj Bhlha15tm3(cre/ERT2)Skz/Bhlha15+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142189
|
Krastm4Tyj/Krastm4Tyj Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:162125
|
Krastm4Tyj/Krastm4Tyj Tg(Cela1-cre/ERT2)1Stof/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142189
|
Krastm4Tyj/Krastm4Tyj Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Krastm4Tyj/Krastm4Tyj Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:151781
|
Krastm4Tyj/Krastm4Tyj Tg(Pdx1-cre/Esr1*)35.10Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Krastm4Tyj/Krastm4Tyj Trim33tm1Los/Trim33tm1Los Tg(Pdx1-cre)89.1Dam/0
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:151781
|
increased pancreatic intraepithelial neoplasia incidence
|
J:151781
|
Krastm5Tyj/Kras+ Pdx1tm1.1(flpo)Most/Pdx1+ Trp53tm1.1Dgk/Trp53+
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:248550
|
increased pancreatic intraepithelial neoplasia incidence
|
J:248550
|
Krastm5Tyj/Kras+ Pdx1tm1.1(flpo)Most/Pdx1+ Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:248550
|
increased pancreatic intraepithelial neoplasia incidence
|
J:248550
|
Krt14tm1.1(cre)Wbm/Krt14+ Tg(KRT14-Snai1)1Efu/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * CD-1)
|
increased sebaceous gland tumor incidence
|
J:229072
|
Lats1tm1Tx/Lats1tm1Tx
(involves: 129S2/SvPas * C57BL/6J)
|
increased ovary tumor incidence
|
J:52536
|
Ldahtm1Mrtn/Ldahtm1Mrtn
(CBACa.129S4(B6)-Ldahtm1Mrtn)
|
increased prostate intraepithelial neoplasia incidence
|
J:101977
|
Lig4tm2.1Fwa/Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:157574
|
ll/ll X/Yaa
(BXSB/MpJScr-ll)
|
increased T cell derived lymphoma incidence
|
J:10973
|
LyarGt(RRG292)Byg/LyarGt(RRG292)Byg Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:263530
|
Lzts1tm1Cro/Lzts1+
(involves: 129 * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:119989
|
Lzts1tm1Cro/Lzts1tm1Cro
(involves: 129 * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:119989
|
Map2k7tm1.1Twad/Map2k7tm1.2Twad Tg(MMTV-cre)4Mam/0 Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:170904
|
increased mammary gland tumor incidence
|
J:170904
|
Map3k1tm1Glj/Map3k1tm1Glj Tg(MMTV-PyVT)634Mul/0
(involves: 129S/SvEv * FVB/N)
|
increased mammary gland tumor incidence
|
J:112298
|
MclrRF/J/MclrSWR/J
(involves: RF/J * SWR/J)
|
increased T cell derived lymphoma incidence
|
J:9614
|
MclrSWR/J/MclrSWR/J
(involves: RF/J * SWR/J)
|
increased T cell derived lymphoma incidence
|
J:9614
|
Mcm2Gt(AB0178)Wtsi/Mcm2+ Mcm4chaos3/Mcm4chaos3
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:165667
|
Mcm3Gt(RRR002)Byg/Mcm3+ Mcm4chaos3/Mcm4chaos3
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:165667
|
Mcm3Gt(RRR002)Byg/Mcm3+ Mcm4chaos3/Mcm4Gt(RRE056)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:165667
|
Mcm4chaos3/Mcm4chaos3
(involves: C57BL/6J)
|
increased mammary gland tumor incidence
|
J:165667
|
increased T cell derived lymphoma incidence
|
J:165667
|
Mcm4chaos3/Mcm4chaos3
(C3.B6-Mcm4chaos3)
|
increased mammary adenocarcinoma incidence
|
J:117494
|
increased mammary gland tumor incidence
|
J:117494
|
Mcm8tm1.1Geno/Mcm8tm1.1Geno
(involves: 129S2/SvPas * C57BL/6J)
|
increased ovary adenoma incidence
|
J:187623
|
increased ovary tumor incidence
|
J:187623
|
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(AW0655)Wtsi
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased ovary tumor incidence
|
J:177420
|
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased ovary tumor incidence
|
J:177420
|
Mcm9Gt(XG743)Byg/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased ovary tumor incidence
|
J:177420
|
Mdm2tm2.1Snj/Mdm2tm2.1Snj
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:189297
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo
(B6.129S6-Mdm2tm3.1Glo)
|
increased mammary adenocarcinoma incidence
|
J:164201
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm3.1Glo Trp53tm3.1Glo)
|
increased mammary adenocarcinoma incidence
|
J:164201
|
Mdm2tm3.1Snj/Mdm2tm3.1Snj
(involves: 129S4/SvJae * C57BL/6)
|
increased salivary gland tumor incidence
|
J:189297
|
Men1tm1.1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
|
increased pancreas tumor incidence
|
J:67128
|
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * FVB/N)
|
increased adrenal gland tumor incidence
|
J:133299
|
increased pancreatic islet cell adenoma incidence
|
J:133299
|
increased parathyroid adenoma incidence
|
J:133299
|
increased pheochromocytoma incidence
|
J:133299
|
increased pituitary adenohypophysis tumor incidence
|
J:133299
|
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:120835
|
increased gland tumor incidence
|
J:120835
|
increased pancreas tumor incidence
|
J:120835
|
increased parathyroid gland tumor incidence
|
J:120835
|
increased pituitary gland tumor incidence
|
J:120835
|
increased testis tumor incidence
|
J:120835
|
increased thyroid tumor incidence
|
J:120835
|
Men1tm1.1Ctre/Men1+ Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J * FVB/N)
|
increased adrenal gland tumor incidence
|
J:133299
|
increased pancreas tumor incidence
|
J:133299
|
increased parathyroid gland tumor incidence
|
J:133299
|
increased pheochromocytoma incidence
|
J:133299
|
increased pituitary adenohypophysis tumor incidence
|
J:133299
|
increased pituitary melanotroph tumor incidence
|
J:133299
|
increased thyroid C-cell carcinoma incidence
|
J:133299
|
Men1tm1.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6)
|
increased adrenal gland adenoma incidence
|
J:116086
|
increased glucagonoma incidence
|
J:116086
|
increased insulinoma incidence
|
J:116086
|
increased Leydig cell tumor incidence
|
J:116086
|
increased ovary tumor incidence
|
J:116086
|
increased pancreas adenoma incidence
|
J:116086
|
increased parathyroid adenoma incidence
|
J:116086
|
increased pituitary adenoma incidence
|
J:116086
|
increased prolactinoma incidence
|
J:116086
|
Men1tm1.2Ctre/Men1+ Tg(Ins2-cre)1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1+ Tg(Ins2-cre)1Heed/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1+ Tg(Ins2-cre)25Mgn/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre Tg(Ins2-cre)1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre Tg(Ins2-cre)1Heed/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre Tg(Ins2-cre)25Mgn/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Zqw/Men1tm1.2Zqw Tg(Ins2-cre)23Herr/0
(involves: 129P2/OlaHsd * C57BL/6J * CBA/J)
|
increased insulinoma incidence
|
J:85133
|
Men1tm1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
|
increased adrenal gland tumor incidence
|
J:67128
|
increased pancreas tumor incidence
|
J:67128
|
increased parathyroid adenoma incidence
|
J:67128
|
increased pheochromocytoma incidence
|
J:67128
|
increased pituitary adenoma incidence
|
J:67128
|
increased prolactinoma incidence
|
J:67128
|
increased thyroid adenoma incidence
|
J:67128
|
Men1tm1Ctre/Men1tm1Ctre Tg(Pdx1-cre)89.1Dam/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased insulinoma incidence
|
J:146440
|
Men1tm1Gfk/Men1tm1Gfk Tg(Ins2-cre)25Mgn/0
(involves: 129T2/SvEms * C57BL/6 * C57BL/6J * DBA)
|
increased insulinoma incidence
|
J:89898
|
increased pancreas tumor incidence
|
J:89898
|
increased prolactinoma incidence
|
J:89898
|
Men1tm1Rvt/Men1+
(involves: 129 * C57BL/6)
|
increased adrenal cortical tumor incidence
|
J:191261
|
increased ovary tumor incidence
|
J:191261
|
increased pancreatic islet cell adenoma incidence
|
J:191261
|
increased parathyroid adenoma incidence
|
J:191261
|
increased parathyroid gland tumor incidence
|
J:191261
|
increased pituitary adenohypophysis tumor incidence
|
J:191261
|
increased pituitary gland tumor incidence
|
J:191261
|
increased testis tumor incidence
|
J:191261
|
increased thyroid tumor incidence
|
J:191261
|
Men1tm1Zqw/Men1+
(involves: 129/Sv * 129P2/OlaHsd)
|
increased adrenal cortical tumor incidence
|
J:85302
|
increased adrenal gland adenoma incidence
|
J:85302
|
increased adrenal gland tumor incidence
|
J:85302
|
increased adrenocortical adenoma incidence
|
J:85302
|
increased gland tumor incidence
|
J:85302
|
increased glucagonoma incidence
|
J:85302
|
increased insulinoma incidence
|
J:85302
|
increased Leydig cell tumor incidence
|
J:85302
|
increased mammary gland tumor incidence
|
J:85302
|
increased ovary tumor incidence
|
J:85302
|
increased pancreas tumor incidence
|
J:85302
|
increased pancreatic islet cell adenoma incidence
|
J:85302
|
increased pancreatic islet cell carcinoma incidence
|
J:85302
|
increased parathyroid adenoma incidence
|
J:85302
|
increased pituitary adenohypophysis tumor incidence
|
J:85302
|
increased prolactinoma incidence
|
J:85302
|
increased testis tumor incidence
|
J:85302
|
increased thyroid carcinoma incidence
|
J:85302
|
increased thyroid tumor incidence
|
J:85302
|
Men1tm2.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6)
|
increased insulinoma incidence
|
J:116086
|
increased Leydig cell tumor incidence
|
J:116086
|
increased ovary tumor incidence
|
J:116086
|
increased pancreas adenoma incidence
|
J:116086
|
increased parathyroid adenoma incidence
|
J:116086
|
increased pituitary adenoma incidence
|
J:116086
|
Men1tm2.1Mmey/Men1tm2.1Mmey Tg(Ins2-cre)23Herr/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N)
|
increased insulinoma incidence
|
J:175625
|
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:151890
|
increased mammary gland tumor incidence
|
J:151890
|
Mgmttm1Mse/Mgmttm1Mse
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:47642
|
Mgmttm1Mse/Mgmttm1Mse Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:47642
|
Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:173230
|
Mir216aem1Uf/Mir216aem1Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir216aem2Uf/Mir216aem2Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir216bem1Uf/Mir216bem1Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir217em1Uf/Mir217em1Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir217em2Uf/Mir217em2Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mirc1tm2.1Aven/Mirc1tm2.1Aven Tg(ARR2/Pbsn-MYC)7Key/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL/J)
|
increased prostate gland adenocarcinoma incidence
|
J:223213
|
Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:47642
|
Mlh1tm1Rak/Mlh1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53451
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53451
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:153684
|
Mmp7tm1Lmm/Mmp7tm1Lmm Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:140033
|
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(MMTV-PyVT)634Mul/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:140033
|
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(MMTV-PyVT)634Mul/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary gland tumor incidence
|
J:140033
|
Mmp11tm1Mrio/Mmp11tm1Mrio Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J * CD-1 * FVB)
|
increased mammary gland tumor incidence
|
J:86074
|
Mnttm1Awb/Mnttm1.1Awb Tg(MMTV-cre)4Mam/?
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:110115
|
Mnttm1Phu/Mnttm1Phu Tg(MMTV-cre)4Mam/?
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:85481
|
Mob1atm1.2Asuz/Mob1a+ Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary gland tumor incidence
|
J:193981
|
increased salivary gland tumor incidence
|
J:193981
|
Mob1atm1.2Asuz/Mob1atm1.2Asuz Mob1bGt(CC0690)Wtsi/Mob1b+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary gland tumor incidence
|
J:193981
|
increased salivary gland tumor incidence
|
J:193981
|
Msh2tm1Htr/Msh2+
(involves: 129P2/OlaHsd)
|
increased mammary gland tumor incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))
|
increased T cell derived lymphoma incidence
|
J:27469
|
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd)
|
increased T cell derived lymphoma incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd * FVB)
|
increased mammary gland tumor incidence
|
J:45433
|
increased T cell derived lymphoma incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr Tap1tm1Hpl/Tap1tm1Hpl
(involves: 129P2/OlaHsd * FVB)
|
increased mammary gland tumor incidence
|
J:45433
|
Msh2tm1Mak/Msh2+ Mutyhtm1Jhmi/Mutyhtm1Jhmi Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased ovary tumor incidence
|
J:89742
|
Msh2tm1Whl/Msh2tm1Whl
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lymphoblastic lymphoma incidence
|
J:79016
|
Msh2tm1Whl/Msh2tm1Whl Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased lymphoblastic lymphoma incidence
|
J:79016
|
increased pheochromocytoma incidence
|
J:79016
|
increased pituitary adenohypophysis tumor incidence
|
J:79016
|
increased pituitary melanotroph tumor incidence
|
J:79016
|
increased thyroid C-cell carcinoma incidence
|
J:79016
|
Msh5tm1Htr/Msh5tm1Htr
(involves: 129P2/OlaHsd * FVB)
|
increased granulosa cell tumor incidence
|
J:180025
|
Msmbtm1Xuan/Msmbtm1Xuan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))
|
increased prostate gland adenocarcinoma incidence
|
J:96884
|
increased prostate intraepithelial neoplasia incidence
|
J:96884
|
Mtes1AKR/J/?
(involves: AKR/J * DBA/2J)
|
increased mammary gland tumor incidence
|
J:73358
|
Mtf1Thyls-BALB/c/Mtf1Thyls-BALB/c
(involves: BALB/c * MSM)
|
increased T cell derived lymphoma incidence
|
J:71358
|
Mtf1Thyls-BALB/c/Mtf1Thyls-MSM
(involves: BALB/c * MSM)
|
increased T cell derived lymphoma incidence
|
J:85264,
J:71358
|
Mtv2a/Mtv2a
(DDD.GR-Mtv2a)
|
increased mammary adenocarcinoma incidence
|
J:109201
|
Muc1tm1Gend/Muc1tm1Gend Tg(WapTgfa)215Bri/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:123146
|
Mutyhtm1Jhmi/Mutyhtm1Jhmi Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased ovary tumor incidence
|
J:89742
|
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
increased T cell derived lymphoma incidence
|
J:195140
|
Nbnem7Jpt/Nbntm2Zqw Tg(VAV1-cre)1Graf/0
(involves: 129P2/OlaHsd)
|
increased T cell derived lymphoma incidence
|
J:277750
|
Nbntm1Xu/Nbntm1Xu
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:75272
|
Nbntm1Zqw/Nbn+
(involves: 129S2/SvPas * C57BL/6)
|
increased Leydig cell tumor incidence
|
J:86563
|
increased mammary adenocarcinoma incidence
|
J:86563
|
increased prostate intraepithelial neoplasia incidence
|
J:86563
|
increased T cell derived lymphoma incidence
|
J:86563
|
increased thyroid adenoma incidence
|
J:86563
|
Ncoa3tm1Jxu/Ncoa3+ Tg(MMTV-vHaras)SH1Led/0
(involves: 129S6/SvEvTac * C57BL/6J * CD-1)
|
increased mammary adenocarcinoma incidence
|
J:88789
|
increased mammary gland tumor incidence
|
J:88789
|
Ndrg2tm1Kmori/Ndrg2+
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
increased pancreas tumor incidence
|
J:210264
|
increased T cell derived lymphoma incidence
|
J:210264
|
increased testis tumor incidence
|
J:210264
|
Ndrg2tm1Kmori/Ndrg2tm1Kmori
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
increased T cell derived lymphoma incidence
|
J:210264
|
Nf1tm1Par/Nf1tm1Par H2az2Tg(Wnt1-cre)11Rth/H2az2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased pheochromocytoma incidence
|
J:80323
|
Nf1tm1Par/Nf1tm1Par Tg(Mpz-cre)94Imeg/0
(involves: 129S1/Sv * 129X1/SvJ)
|
increased pheochromocytoma incidence
|
J:80323
|
Nf1tm1Par/Nf1tm1Par Tg(Pax3-cre)1Joe/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased pheochromocytoma incidence
|
J:80323
|
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:18542
|
increased pheochromocytoma incidence
|
J:18542
|
Nf2tm1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2+ Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth Ptgdstm1.1(cre)Gvn/Ptgds+
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:173718
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:132943
|
Nhej1tm1Fwa/Nhej1tm1Fwa Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129)
|
increased T cell derived lymphoma incidence
|
J:138774
|
Nkx3-1tm1Mms/Nkx3-1+ Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate gland tumor incidence
|
J:75085
|
increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Nkx3-1tm1Mms/Nkx3-1tm1Mms
(involves: 129S1/Sv)
|
increased prostate intraepithelial neoplasia incidence
|
J:131932
|
Nkx3-1tm1Mms/Nkx3-1tm1Mms Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate gland tumor incidence
|
J:75085
|
increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Nkx3-1tm1Saa/Nkx3-1tm1Saa Tg(KLK3-cre)13Saa/?
(involves: C57BL/6)
|
increased prostate intraepithelial neoplasia incidence
|
J:74350
|
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:153425
|
increased prostate intraepithelial neoplasia incidence
|
J:191327,
J:153425
|
Nmitm1.1Geno/Nmitm1.1Geno Tg(KRT14-cre)1Amc/0 Tg(MMTVneu)202Mul/0
(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:261035
|
Nr0b1tm1.1Lja/Y
(involves: 129S1/Sv * 129X1/SvJ)
|
increased testis tumor incidence
|
J:71710
|
Nsmce2Gt(AA0032)Wtsi/Nsmce2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pancreas tumor incidence
|
J:227197
|
Palb2tm1.1Dli/Palb2tm1.1Dli Trp53tm1Brn/Trp53+ Tg(KRT14-cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:197442
|
Palb2tm1.1Dli/Palb2tm1.1Dli Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:197442
|
Pcsk2tm1Dfs/Pcsk2tm1Dfs
(B6;129-Pcsk2tm1Dfs/J)
|
increased glucagonoma incidence
|
J:236511
|
increased pancreas tumor incidence
|
J:236905
|
increased pancreatic ductal adenocarcinoma incidence
|
J:236905
|
increased pancreatic islet cell adenoma incidence
|
J:236905
|
Pcsk6tm1Rob/Pcsk6tm1Rob
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased ovary tumor incidence
|
J:180839
|
Per2tm1Ccl/Per2tm1Ccl
(involves: 129 * C57BL/6)
|
increased salivary gland tumor incidence
|
J:79456
|
Pgct1129S1/SvImJ/?
(involves: 129S1/SvImJ * C57BL/6J)
|
increased testis tumor incidence
|
J:63413
|
Pik3catm1.1Waph/Pik3ca+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * BALB/c * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:184382
|
increased ovary tumor incidence
|
J:184382
|
Pik3catm1.1Waph/Pik3ca+ Tg(MMTV-cre)#Mam/0
(involves: 129S1/Sv * C57BL/6 * FVB)
|
increased fibroadenoma incidence
|
J:187299
|
increased mammary adenoacanthoma incidence
|
J:187299
|
increased mammary gland tumor incidence
|
J:187299
|
Pik3catm1Gne/Pik3ca+ Tg(MMTV-cre)1Mam/0
(involves: C57BL/6N * FVB/N)
|
increased mammary gland tumor incidence
|
J:193377
|
Pik3catm1Jjz/Pik3catm1Jjz Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:138565
|
Pinx1tm1.1Kplu/Pinx1+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased Harderian gland adenoma incidence
|
J:171997
|
increased mammary gland tumor incidence
|
J:171997
|
Pinx1tm1.1Kplu/Pinx1+ Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:171997
|
increased ovary tumor incidence
|
J:171997
|
Pinx1tm1.1Kplu/Pinx1+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:171997
|
Plbcq6M16i/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Pldmq1FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Pldmq3FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Pldmq4FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Pldmq5FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Plgtm1Jld/Plgtm1Jld Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * Black Swiss * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48285
|
Pmltm1.1Ews/Pmltm1.1Ews
(involves: 129 * 129P2/OlaHsd)
|
increased T cell derived lymphoma incidence
|
J:262172
|
Pmltm1Ppp/Pml+ Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
|
increased T cell derived lymphoma incidence
|
J:317504
|
Pmltm1Ppp/Pmltm1Ppp Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
|
increased T cell derived lymphoma incidence
|
J:317504
|
Pms2tm1.1Wed/Pms2tm1.1Wed
(involves: 129S6/SvEvTac * C57BL/6NCr)
|
increased T cell derived lymphoma incidence
|
J:162378
|
Poats1C57BL/6JCrl/Poats1C57BL/6JCrl
(involves: C57BL/6JCrl * DBA/2JCrl)
|
increased adrenal gland tumor incidence
|
J:131752
|
Pold1tm1.1Bdp/Pold1tm1.1Bdp
(B6.129-Pold1tm1.1Bdp)
|
increased T cell derived lymphoma incidence
|
J:153684
|
Pold1tm1.1Bdp/Pold1tm1.1Bdp Poletm1.1Bdp/Poletm1.1Bdp
(B6.129-Poletm1.1Bdp Pold1tm1.1Bdp)
|
increased T cell derived lymphoma incidence
|
J:153684
|
Pold1tm1Bdp/Pold1tm1Bdp
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:100685
|
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:261973
|
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg Trp53tm1Brd/Trp53+
(involves: C57BL/6J * C57BL/6NTac)
|
increased T cell derived lymphoma incidence
|
J:261973
|
Pomctm1Low/Pomc+
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomc+ Tg(Pomc)#Low/0
(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomctm1Low
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomctm1Low Tg(Pomc)#Low/0
(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster)
|
increased pituitary adenoma incidence
|
J:119240
|
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * C57BL/6N)
|
increased sebaceous gland adenoma incidence
|
J:90337
|
Prdm2tm1Shg/Prdm2+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary adenoma incidence
|
J:71406
|
Prdm2tm1Shg/Prdm2tm1Shg
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary adenoma incidence
|
J:71406
|
Prdx1tm1Rave/Prdx1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:84677
|
Prdx1tm1Rave/Prdx1tm1Rave
(involves: 129S6/SvEvTac * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:84677
|
increased pancreatic islet cell adenoma incidence
|
J:84677
|
increased T cell derived lymphoma incidence
|
J:84677
|
Prf1tm1Sdz/Prf1tm1Sdz
(C.B6-Prf1tm1Sdz)
|
increased T cell derived lymphoma incidence
|
J:77491
|
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased thyroid tumor incidence
|
J:98799
|
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased thyroid tumor incidence
|
J:160299
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Ptentm1.1Mwst/Ptentm1.1Mwst Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:225245
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Tg(Ghrhr-cre)3242Lsk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased pituitary gland tumor incidence
|
J:130264
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:225245,
J:241066
|
Prkdcscid/Prkdcscid
(C.BKa-Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:6958
|
Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:109833,
J:22026
|
Prkdctm1Gcl/Prkdctm1Gcl
(involves: 129S1/Sv * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53765
|
Prltm1Hmn/Prltm1Hmn
(involves: 129S2/SvPas)
|
increased pituitary adenoma incidence
|
J:79661
|
Prlrtm1Cnp/Prlrtm1Cnp
(involves: 129/Sv * 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:101609
|
Prlrtm1Cnp/Prlrtm1Cnp Tg(C3-1-TAg)cJeg/0
(involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:84352
|
Pscatm1Witt/Psca+ Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
increased prostate gland tumor incidence
|
J:133908
|
increased prostate intraepithelial neoplasia incidence
|
J:133908
|
Pscatm1Witt/Pscatm1Witt Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
increased prostate gland tumor incidence
|
J:133908
|
increased prostate intraepithelial neoplasia incidence
|
J:133908
|
Ptch1tm1Mps/Ptch1+ Ptch2tm1Pmc/Ptch2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased testicular teratoma incidence
|
J:112118
|
Ptentm1.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
increased mammary gland tumor incidence
|
J:158751
|
increased prostate gland tumor incidence
|
J:158751
|
increased T cell derived lymphoma incidence
|
J:158751
|
increased thyroid tumor incidence
|
J:158751
|
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * BALB/c)
|
increased mammary adenocarcinoma incidence
|
J:110567
|
increased prostate gland tumor incidence
|
J:110567
|
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac)
|
increased thyroid adenoma incidence
|
J:170965
|
Ptentm1.1Hwu/Pten+ Tmprss2tm1.1(ERG)Sho/Tmprss2tm1.1(ERG)Sho
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Ptentm1.1Hwu/Pten+ Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Ptentm1.1Mro/Pten+
(Not Specified)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1.1Mro/Pten+ Sdhbtm1.2Ics/Sdhb+
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1.1Mwst/Ptentm1.1Mwst Tg(MMTVneu)202Mul/0 Tg(S100a4-cre)1Gle/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153747
|
increased mammary gland tumor incidence
|
J:153747
|
Ptentm1.1Mwst/Ptentm1.1Mwst Tg(S100a4-cre)1Gle/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:153747
|
Ptentm1.2Mwst/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
increased mammary adenoacanthoma incidence
|
J:158751
|
increased mammary gland tumor incidence
|
J:158751
|
increased prostate gland tumor incidence
|
J:158751
|
increased T cell derived lymphoma incidence
|
J:158751
|
increased thyroid tumor incidence
|
J:158751
|
Ptentm1Hwu/Pten+ Tg(ARR2/Pbsn-FGF8)3Prb/0 Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:106650
|
increased prostate intraepithelial neoplasia incidence
|
J:106650
|
Ptentm1Hwu/Pten+ Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased mammary adenocarcinoma incidence
|
J:138927
|
increased mammary gland tumor incidence
|
J:138927
|
Ptentm1Hwu/Pten+ Tg(Nkx2-1-cre)2Sand/0
(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand)
|
increased thyroid tumor incidence
|
J:197590
|
Ptentm1Hwu/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:93902
|
Ptentm1Hwu/Pten+ Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:212219
|
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
|
increased prostate gland adenocarcinoma incidence
|
J:144810
|
increased prostate intraepithelial neoplasia incidence
|
J:144810
|
Ptentm1Hwu/Ptentm1Hwu Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:142150,
J:222579
|
Ptentm1Hwu/Ptentm1Hwu Cop1tm2.1Vmd/Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
|
increased prostate gland adenocarcinoma incidence
|
J:172653
|
increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Ptentm1Hwu/Ptentm1Hwu Ptpn1tm1Bpk/Ptpn1tm1Bpk Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:231906
|
increased prostate intraepithelial neoplasia incidence
|
J:231906
|
Ptentm1Hwu/Ptentm1Hwu Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0 Tg(TPO-cre)1Shk/0
(involves: 129S4/SvJae * FVB/NCr * FVB/NJ)
|
increased thyroid carcinoma incidence
|
J:177181
|
Ptentm1Hwu/Ptentm1Hwu Tg(CAG-MYC,-GFP*)#Rugg/0 Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:261540
|
increased prostate intraepithelial neoplasia incidence
|
J:261540
|
Ptentm1Hwu/Ptentm1Hwu Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * FVB/N)
|
increased prostate gland tumor incidence
|
J:106662
|
Ptentm1Hwu/Ptentm1Hwu Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased mammary adenocarcinoma incidence
|
J:138927
|
increased mammary gland tumor incidence
|
J:138927
|
increased thyroid tumor incidence
|
J:138927
|
Ptentm1Hwu/Ptentm1Hwu Tg(MMTV-cre)#Tfln/0
(involves: 129S4/SvJae)
|
increased fibroadenoma incidence
|
J:78415
|
increased mammary adenocarcinoma incidence
|
J:78415
|
increased mammary gland tumor incidence
|
J:78415
|
Ptentm1Hwu/Ptentm1Hwu Tg(Nkx2-1-cre)2Sand/0
(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand)
|
increased thyroid adenoma incidence
|
J:197590
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:142106
|
increased prostate gland tumor incidence
|
J:142106
|
increased prostate intraepithelial neoplasia incidence
|
J:138565
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:268934,
J:184935,
J:212219
|
increased prostate gland tumor incidence
|
J:268934,
J:172730,
J:170965
|
increased prostate intraepithelial neoplasia incidence
|
J:268934,
J:131932,
J:212219
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:93902,
J:124208
|
increased prostate gland tumor incidence
|
J:124208
|
increased prostate intraepithelial neoplasia incidence
|
J:93902,
J:106650
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:238768
|
increased prostate intraepithelial neoplasia incidence
|
J:238768
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:102226
|
increased pancreatic intraepithelial neoplasia incidence
|
J:102226
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic acinar cell carcinoma incidence
|
J:102226
|
increased pancreatic ductal adenocarcinoma incidence
|
J:102226
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pgc-cre,-secNluc)#Hcz/0
(involves: 129S4/SvJae)
|
increased mammary adenocarcinoma incidence
|
J:338079
|
Ptentm1Hwu/Ptentm1Hwu Trp53tm2Tyj/Trp53+ Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:222579
|
increased ovarian carcinoma incidence
|
J:222579
|
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased adrenal gland tumor incidence
|
J:63478
|
increased fibroadenoma incidence
|
J:63478
|
increased mammary adenocarcinoma incidence
|
J:63478
|
increased mammary gland tumor incidence
|
J:63478
|
increased prostate gland tumor incidence
|
J:63478
|
increased T cell derived lymphoma incidence
|
J:50437
|
Ptentm1Mak/Pten+
(B6.129P2-Ptentm1Mak)
|
increased adrenal gland tumor incidence
|
J:93530
|
Ptentm1Mro/Pten+ Sdhbtm1.1Ics/Sdhb+ Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Mro/Pten+ Tg(KLK3-cre)D4Trp/0
(involves: 129P2/OlaHsd * FVB)
|
increased prostate gland adenocarcinoma incidence
|
J:99524
|
increased prostate gland tumor incidence
|
J:99524
|
increased prostate intraepithelial neoplasia incidence
|
J:99524
|
Ptentm1Mro/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:184533
|
Ptentm1Mro/Ptentm1Mro Sdhbtm1.1Ics/Sdhb+ Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Mro/Ptentm1Mro Sdhbtm1.1Ics/Sdhbtm1.2Ics Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * BALB/c * C57BL/6 * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Ppp/Pten+ Tg(Pbsn-TAg)15Tvd/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:103408
|
increased prostate gland tumor incidence
|
J:103408
|
increased prostate intraepithelial neoplasia incidence
|
J:103408
|
Ptentm1Ppp/Ptentm2Ppp
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:86212
|
Ptentm1Rdp/Ptentm1Rdp Smad4tm1Rdp/Smad4tm1Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Terttm1Rdp/Tert+ Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Terttm1Rdp/Terttm1Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Terttm3Rdp/Terttm3Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rps/Pten+
(involves: 129S1/Sv * C57BL/6J)
|
increased prostate intraepithelial neoplasia incidence
|
J:53065
|
increased thyroid carcinoma incidence
|
J:53065
|
Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Ptentm1Rps/Pten+ Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:67497
|
increased mammary gland ductal carcinoma incidence
|
J:67497
|
increased salivary adenocarcinoma incidence
|
J:67497
|
Ptentm2.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
increased mammary adenoacanthoma incidence
|
J:158751
|
increased mammary gland tumor incidence
|
J:158751
|
increased prostate gland tumor incidence
|
J:158751
|
increased T cell derived lymphoma incidence
|
J:158751
|
increased thyroid tumor incidence
|
J:158751
|
Ptentm2.1Ppp/Pten+ Spry1tm1Jdli/Spry1tm1.1Jdli Spry2tm1Mrt/Spry2tm1.1Mrt Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased prostate gland tumor incidence
|
J:192348
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Ptentm2.1Ppp Rb1tm2Brn/Rb1tm2Brn Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:307910
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(CAG-Bgeo,-Spry2,-ALPP)1Mrt/0 Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:163589,
J:100683
|
increased prostate gland tumor incidence
|
J:86212,
J:100683
|
increased prostate intraepithelial neoplasia incidence
|
J:239660,
J:163589,
J:100683,
J:200002
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)8113ANg/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:86212
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129S1.Cg-Ptentm2.1Ppp Tg(TPO-cre)1Shk)
|
increased thyroid adenoma incidence
|
J:165293
|
increased thyroid carcinoma incidence
|
J:165293
|
Ptentm2.1Ppp/Ptentm2.1Ppp Trp53tm1Brn/Trp53tm1Brn Tg(TPO-cre)1Shk/0
(129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp)
|
increased thyroid carcinoma incidence
|
J:211100
|
Ptentm2.1Ppp/Ptentm2.1Ppp Trp53tm1Thl/Trp53tm1Thl Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:100683
|
Ptentm2Mak/Ptentm2Mak Tg(KLK3-cre)13Saa/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:214242
|
increased prostate gland tumor incidence
|
J:214242
|
increased prostate intraepithelial neoplasia incidence
|
J:214242
|
Ptentm2Mak/Ptentm2Mak Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
increased mammary gland tumor incidence in breeding females
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
increased mammary gland tumor incidence in breeding females
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
Ptpn11tm1Ckq/Ptpn11+ Tg(Lck-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased lymphoblastic lymphoma incidence
|
J:177285
|
Ptpn11tm1Ckq/Ptpn11+ Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA)
|
increased lymphoblastic lymphoma incidence
|
J:177285
|
Ptprctm1Holm/Ptprctm1Holm Tg(Lck*F505)2964Rmp/?
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:64671
|
Ptprctm1Holm/Ptprctm1Holm Tg(Lck*F505)3073Rmp/?
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:64671
|
Puf60tm1.1Kmtsu/Puf60+ Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj)
|
increased T cell derived lymphoma incidence
|
J:233347
|
Rad50tm2Jpt/Rad50tm2Jpt
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))
|
increased T cell derived lymphoma incidence
|
J:78820
|
Rad50tm2Jpt/Rad50tm2Jpt Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:78820
|
Rag1tm1Jsek/Rag1tm1Jsek Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:146912
|
Rag1tm1Mom/Rag1+ Tg(LPV-TAg1135)11Tvd/0
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1+ Tg(LPV-TAg1135)11Tvd/0 Tg(TcrLCMV)327Sdz/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom Prf1tm1Sdz/Prf1tm1Sdz
(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz)
|
increased T cell derived lymphoma incidence
|
J:109843
|
Rag1tm1Mom/Rag1tm1Mom Tg(LPV-TAg1135)11Tvd/0
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom Tg(LPV-TAg1135)11Tvd/0 Tg(TcrLCMV)327Sdz/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL)
|
increased pituitary adenoma incidence
|
J:141515
|
increased T cell derived lymphoma incidence
|
J:141515
|
Rag1tm1Mom/Rag1tm1Mom Trp53tm1Brd/Trp53tm1Brd Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL)
|
increased T cell derived lymphoma incidence
|
J:141515
|
Rag2tm1.1Desi/Rag2tm1.1Desi Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:168974
|
Rag2tm1.1Mss/Rag2tm1.1Mss Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:170462
|
Rag2tm1Fwa/Rag2+ Tg(LPV-TAg1135)11Tvd/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2tm1Fwa Stat1tm1Rds/Stat1tm1Rds
(involves: 129S/SvEv * 129S6/SvEvTac)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: 129S/SvEv * C57BL/6 * Swiss Webster)
|
increased T cell derived lymphoma incidence
|
J:235890
|
increased thymus tumor incidence
|
J:235890
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(LPV-TAg1135)11Tvd/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2tm1Fwa Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm2.1Desi/Rag2tm2.1Desi Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:168974
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd Tg(MMTVneu)202Mul/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:202603
|
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
|
increased testicular teratoma incidence
|
J:102483
|
Rb1tm1Brd/Rb1+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased pituitary adenoma incidence
|
J:17434
|
Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased pheochromocytoma incidence
|
J:79016
|
increased pituitary adenohypophysis tumor incidence
|
J:79016
|
increased pituitary melanotroph tumor incidence
|
J:79016
|
increased thyroid C-cell carcinoma incidence
|
J:79016
|
Rb1tm1Brn/Rb1+ Tg(Pomc-FLP)1aBrn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Brn/Rb1tm1Brn Tg(Pomc-FLP)1aBrn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Brn/Rb1tm1Brn X/Tg(Pomc-FLP)1bBrn
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Mlh/Rb1+
(either: 129P2/OlaHsd-Rb1tm1Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
|
increased pituitary melanotroph tumor incidence
|
J:20542
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:81082,
J:2511
|
increased thyroid tumor incidence
|
J:81082
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6J)
|
increased pheochromocytoma incidence
|
J:133299
|
increased pituitary adenohypophysis tumor incidence
|
J:133299
|
increased pituitary melanotroph tumor incidence
|
J:133299
|
increased thyroid C-cell carcinoma incidence
|
J:133299
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
increased thyroid tumor incidence
|
J:175625
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas)
|
increased pituitary gland tumor incidence
|
J:215358
|
Rb1tm1Tyj/Rb1+ Rbl1tm1Tyj/Rbl1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:34058
|
Rb1tm1Tyj/Rb1+ Rbl1tm1Tyj/Rbl1tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:34058
|
Rb1tm1Tyj/Rb1+ Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
|
increased pituitary gland tumor incidence
|
J:132091
|
Rb1tm1Tyj/Rb1+ Trim27Gt(XP0484)Wtsi/Trim27Gt(XP0484)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:189317
|
increased thyroid tumor incidence
|
J:189317
|
Rb1tm1Tyj/Rb1+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased pancreatic islet cell carcinoma incidence
|
J:19542
|
increased pituitary melanotroph tumor incidence
|
J:19542
|
increased thyroid tumor incidence
|
J:19542
|
Rb1tm1Tyj/Rb1tm2Tyj
(chimera involves: 129S2/SvPas * C57BL/6)
|
increased pituitary adenoma incidence
|
J:59268
|
Rb1tm2Brn/Rb1tm2Brn Tg(Gfap-cre)2Brn/0
(involves: 129 * FVB/N)
|
increased pituitary gland tumor incidence
|
J:187257
|
Rb1tm2Brn/Rb1tm2Brn Tg(Rbp3-cre)1Brn/0
(involves: 129 * FVB/N)
|
increased pituitary adenohypophysis tumor incidence
|
J:77982
|
increased pituitary melanotroph tumor incidence
|
J:77982
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased ovarian carcinoma incidence
|
J:84345
|
increased ovary tumor incidence
|
J:84345
|
increased thyroid carcinoma incidence
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Gfap-cre)2Brn/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased pituitary gland tumor incidence
|
J:187257
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Rb1tm2Brn Tg(MMTV-cre)105Ayn)
|
increased mammary gland tumor incidence
|
J:165292
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Ren-cre)#Kwg/0
(involves: 129 * 129P2/OlaHsd)
|
increased glucagonoma incidence
|
J:216559
|
increased pancreatic islet cell carcinoma incidence
|
J:216559
|
Rb1tm2Mlh/Rb1+
(either: 129P2/OlaHsd-Rb1tm2Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
|
increased pituitary melanotroph tumor incidence
|
J:20542
|
Rb1tm3Tyj/Rb1tm3Tyj Tg(Nes-cre)1Atp/0
(involves: 129S4/SvJae * FVB/N)
|
increased pituitary gland tumor incidence
|
J:91406
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Atp/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased pituitary gland tumor incidence
|
J:91406
|
Rc3h1san/Rc3h1+
(involves: C57BL/6JSfdAnu)
|
increased T cell derived lymphoma incidence
|
J:189087
|
Rettm1Giro/Ret+
(129.129P2-Rettm1Giro)
|
increased thyroid adenoma incidence
|
J:141658
|
Rettm2.1Cos/Rettm2.1Cos
(involves: 129S1/Sv * C57BL/6J * FVB/N)
|
increased pheochromocytoma incidence
|
J:60659
|
Rettm2.1Cos/Rettm2.1Cos
(involves: 129S1/Sv * C57BL/6J)
|
increased pheochromocytoma incidence
|
J:148708
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:158922
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:158922
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd Trp53tm1Brd/Trp53tm1Brd Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:158922
|
Rgs5tm1.1Rgan/Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh)
|
increased insulinoma incidence
|
J:136259
|
Rgsc142/Rgsc142+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased T cell derived lymphoma incidence
|
J:133634
|
Rgsc1033/Rgsc1033+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pituitary adenoma incidence
|
J:133634
|
increased thyroid carcinoma incidence
|
J:133634
|
Rgsc1324/Rgsc1324+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pheochromocytoma incidence
|
J:133634
|
Rgsc1328/Rgsc1328+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pheochromocytoma incidence
|
J:133634
|
Rhoctm1Mak/Rhoctm1Mak Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:100482
|
Rint1tm1Whl/Rint1+
(Not Specified)
|
increased mammary adenocarcinoma incidence
|
J:122805
|
increased mammary gland tumor incidence
|
J:122805
|
increased ovary tumor incidence
|
J:122805
|
increased pituitary adenoma incidence
|
J:122805
|
Rnf8Gt(AS0574)Wtsi/Rnf8Gt(AS0574)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:161240
|
increased T cell derived lymphoma incidence
|
J:161240
|
Rnf8Gt(RRR260)Byg/Rnf8Gt(RRR260)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:161240
|
increased T cell derived lymphoma incidence
|
J:161240
|
Rps6kb2tm1Gtho/Rps6kb2tm1Gtho Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Rps6kb2tm1Gtho Tg(Ins2-Akt1*)3Mbb)
|
increased insulinoma incidence
|
J:144599
|
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6N)
|
increased T cell derived lymphoma incidence
|
J:223276
|
Rr149356tm1Che/Rr149356tm1Che Tcrdtm1Mom/Tcrdtm1Mom Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:106246
|
Rr149356tm1Che/Rr149356tm1Che Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:106246
|
Runx1tm1(RUNX1)Gcg/Runx1tm1(RUNX1)Gcg Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:106800
|
Runx1tm1Spe/Runx1+
(either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca))
|
increased T cell derived lymphoma incidence
|
J:80829
|
Runx1tm2Buch/Runx1tm2Buch Tg(Mx1-cre)1Cgn/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:105709
|
Runx1tm3Dow/Runx1+ Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:77129
|
Rxratm1Krc/Rxra+ Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:78553
|
Rxratm1Krc/Rxratm1Krc Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:78553
|
S100a4tm1Amba/S100a4tm1Amba
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
|
increased mammary adenocarcinoma incidence
|
J:89563
|
Sav1tm1Dlim/Sav1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased ovary tumor incidence
|
J:160325
|
Scribtm1.1Phum/Scribtm1.1Phum Tg(Pbsn-cre)20Fwan/0
(involves: FVB/NCrl)
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Sf1Gt(XD130)Byg/Sf1+
(involves: 129P2/OlaHsd * 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:164224
|
Shc1tm5Paw/Shc1+ Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Shc1tm5Paw/Shc1tm5Paw Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Shc1tm6Paw/Shc1+ Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Shc1tm6Paw/Shc1tm6Paw Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Shc1tm7Paw/Shc1+ Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Sirt2tm1.1Cxd/Sirt2tm1.1Cxd
(either: (involves: C57BL/6 * FVB/N) or (involves: FVB/N * NIH Black Swiss))
|
increased mammary gland tumor incidence
|
J:177486
|
increased pancreas tumor incidence
|
J:177486
|
increased prostate gland tumor incidence
|
J:177486
|
Skiltm1Sis/Skil+
(involves: C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:62174
|
Smad4m4Mag/Smad4+
(involves: 129S/Sv * Black Swiss * C57BL/6)
|
increased ovary tumor incidence
|
J:106440
|
Smad4tm1.1Gsu/Smad4tm1.1Gsu Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(MtTGFA)Lmb/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:229184
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)7Mul/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:212549
|
Smarca2tm1Mya/Smarca2tm1Mya Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
|
increased mammary gland tumor incidence
|
J:132091
|
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * C57BL/6J * CD-1)
|
increased mammary adenocarcinoma incidence
|
J:132091
|
Smarcb1tm1Sho/Smarcb1tm3Sho Tg(Mx1-cre)1Cgn/?
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:80224
|
Spi1tm1.1Dgt/Spi1tm1.1Dgt
(involves: 129S1/Sv * 129X1/SvJ)
|
increased T cell derived lymphoma incidence
|
J:90331
|
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:106040
|
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129 * BALB/c * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:90331
|
Spry1tm1Jdli/Spry1tm1.1Jdli Spry2tm1Mrt/Spry2tm1.1Mrt Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac)
|
increased adrenal cortical tumor incidence
|
J:166879
|
increased ovary tumor incidence
|
J:166879
|
increased testis tumor incidence
|
J:166879
|
increased thyroid carcinoma incidence
|
J:166879
|
Srctm1Mul/Src+ Tg(MMTV-cre)7Mul/0 Tg(MMTV-PyVT)#Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:181822
|
Srctm1Mul/Srctm1Mul Tg(MMTV-cre)7Mul/0 Tg(MMTV-PyVT)#Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:181822
|
Srpxtm1Hzi/Srpxtm1Hzi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:119999
|
Ssbp2tm1Lana/Ssbp2tm1Lana Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:162035
|
Stat1tm1Dlv/Stat1tm1Dlv
(B6.129S-Stat1tm1Dlv)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Stat1tm1Rds/Stat1tm1Rds
(129S6/SvEv-Stat1tm1Rds/Tac)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Stat3tm4Vpo/Stat3tm4Vpo Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CD-1 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:157976
|
increased mammary gland tumor incidence
|
J:157976
|
Stk3tm1.1Jav/Stk3tm1.1Jav
(involves: 129 * C57BL/6)
|
increased mammary gland tumor incidence
|
J:153945
|
Stk11tm1Mmt/Stk11+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * 129X1/SvJ)
|
increased ovary tumor incidence
|
J:107275
|
Stk11tm1Rdp/Stk11tm1Rdp Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased mammary gland tumor incidence
|
J:198481
|
Stk38tm1Hem/Stk38+
(involves: 129P2/Ola * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:185408
|
Stk38tm1Hem/Stk38tm1Hem
(involves: 129P2/Ola * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:185408
|
Suprmam1BALB/cMed/Suprmam1BALB/cMed Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * BALB/cMed * C57BL/6 * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:122161
|
T(9;17)138Ca/T(9;17)138Ca
(Not Specified)
|
increased mammary gland tumor incidence
|
J:169366
|
Tbrg1tm1a(KOMP)Wtsi/Tbrg1tm1a(KOMP)Wtsi
(C57BL/6N-Tbrg1tm1a(KOMP)Wtsi)
|
increased Harderian gland adenoma incidence
|
J:225146
|
Tbx21tm1Glm/Tbx21tm1Glm Tg(TRAMP)8247Ng/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:88093
|
increased prostate gland tumor incidence
|
J:88093
|
increased prostate intraepithelial neoplasia incidence
|
J:88093
|
Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:44278
|
Tcf3tm2Wein/Tcf3tm2Wein
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:47671
|
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd)
|
increased mammary adenoacanthoma incidence
|
J:57721
|
Tg(ACTB-Artn)1Wss/0
(involves: C57BL/6Crl * DBA/2Crl)
|
increased adrenal gland tumor incidence
|
J:90843
|
Tg(AMH-Fshr)27Hht/0
(involves: FVB/N)
|
increased ovarian teratoma incidence
|
J:160015
|
Tg(AMH-Fshr*D580H)#Hht/0
(involves: FVB/N)
|
increased ovarian carcinoma incidence
|
J:160015
|
increased ovarian teratoma incidence
|
J:160015
|
increased prolactinoma incidence
|
J:160015
|
Tg(AMH-Fshr*D580Y)#Hht/0
(involves: FVB/N)
|
increased ovarian teratoma incidence
|
J:160015
|
Tg(Amh-SMAD2*)#Jebu/0
(FVB/N-Tg(Amh-SMAD2*)#Jebu)
|
increased ovarian teratoma incidence
|
J:200783
|
increased ovary tumor incidence
|
J:200783
|
Tg(Amh-SMAD2*)#Jebu/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased ovarian teratoma incidence
|
J:200783
|
Tg(Amhr2-SV40TAg)1Dcco/0
((C57BL/6 x C3H)F1)
|
increased ovarian carcinoma incidence
|
J:82550
|
increased ovary tumor incidence
|
J:82550
|
increased testis tumor incidence
|
J:82550
|
Tg(APOE-Artn)1Wss/0
(involves: C57BL/6Crl * DBA/2Crl)
|
increased adrenal gland tumor incidence
|
J:90843
|
Tg(ARR2/Pbsn-FGF8)3Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:106650,
J:78918
|
Tg(Arr2/Pbsn-FGFR1K656E)1Wmck/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(Arr2/Pbsn-FGFR1K656E)1Wmck/0 Tg(Pbsn-FGFR2_iiib*)#Ng/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(ARR2/Pbsn-MYC)7Key/?
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:223213,
J:85480
|
increased prostate gland tumor incidence
|
J:85480
|
increased prostate intraepithelial neoplasia incidence
|
J:223213,
J:85480
|
Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
increased T cell derived lymphoma incidence
|
J:93111
|
Tg(BCL2OVARY)1Ah/0
(involves: FVB)
|
increased ovarian teratoma incidence
|
J:55158
|
Tg(BLG-STAT5A)6Itb/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:80588
|
Tg(BLG-STAT5A)15Itb/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:80588
|
Tg(C3-1-TAg)cJeg/0
(involves: FVB/N)
|
increased bulbourethral gland adenocarcinoma incidence
|
J:46513
|
increased mammary adenocarcinoma incidence
|
J:52786,
J:46513
|
increased prostate gland adenocarcinoma incidence
|
J:52786,
J:46513,
J:72324
|
increased prostate intraepithelial neoplasia incidence
|
J:46513,
J:72324
|
Tg(C3-1-TAg)cJeg/0
(FVB/N-Tg(C3-1-TAg)cJeg)
|
increased prostate gland tumor incidence
|
J:84352
|
increased prostate intraepithelial neoplasia incidence
|
J:84352
|
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0 Tg(Pdx1-cre)6Tuv/0 Tg(tetO-MYC)36Bop/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pancreas tumor incidence
|
J:197052
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197052
|
increased pancreatic intraepithelial neoplasia incidence
|
J:197052
|
Tg(CAG-cat,-ALOX15)1868Klv/0 Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:114903
|
Tg(CAG-cat,-ALOX15)1868Klv/Tg(CAG-cat,-ALOX15)1868Klv Tg(Pbsn-cre)4Prb/?
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:114903
|
Tg(CAG-Has2)99Nita/0 Tg(MMTV-cre)4Mam/0 Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:130531,
J:164205
|
increased mammary gland tumor incidence
|
J:164205
|
Tg(CAG-Has2)99Nita/0 Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:130531
|
Tg(CAG-lacZ,-SV40)#Bcv/0
(involves: FVB/N)
|
increased ovarian carcinoma incidence
|
J:158388
|
increased ovary tumor incidence
|
J:158388
|
increased pancreas tumor incidence
|
J:158388
|
Tg(CD2-Tgfbr2)1Grs/?
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)
|
increased T cell derived lymphoma incidence
|
J:93665
|
Tg(Cd4-NPM/ALK)N1Ingh/0
(either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster))
|
increased lymphoblastic lymphoma incidence
|
J:82127
|
Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: C57BL/6 * Swiss Webster)
|
increased thymus tumor incidence
|
J:235890
|
Tg(Cd4-NPM/ALK)N1Ingh/0 Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * Swiss Webster)
|
increased T cell derived lymphoma incidence
|
J:235890
|
Tg(Cela1-luc,Cela1-TAg)#Nzh/0
(involves: FVB/N)
|
increased ovary tumor incidence
|
J:207960
|
increased pancreatic acinar cell carcinoma incidence
|
J:207960
|
Tg(Cga-LHB/CGB)94Jhn/?
(involves: C57BL/6 * SJL)
|
increased ovary tumor incidence
|
J:55157
|
Tg(CMV-tTA)3Bjd/0 Tg(tetO-Prkar1a*x2as)1Stra/0
(involves: C57BL/6 * NMRI * SJL)
|
increased thyroid adenoma incidence
|
J:95465,
J:94953
|
Tg(Cyp19)C2-3Rrte/0
(involves: BALB/c * C57BL/6)
|
increased fibroadenoma incidence
|
J:34063
|
increased mammary gland tumor incidence
|
J:78693
|
Tg(Ela1-Myc)158Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:76992
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-Myc)159Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:76992
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-Myc)160Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:76992
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * SJL)
|
increased insulinoma incidence
|
J:76995
|
increased pancreas tumor incidence
|
J:76995
|
increased pancreatic acinar cell carcinoma incidence
|
J:76995
|
increased pancreatic islet cell adenoma incidence
|
J:76995
|
Tg(Ela1-TAg)19Bri/0
(involves: C57BL/6 * SJL)
|
increased insulinoma incidence
|
J:76995
|
increased pancreas tumor incidence
|
J:76995
|
increased pancreatic acinar cell carcinoma incidence
|
J:76995
|
Tg(Ela1-TAg*)79Mjt/0
(involves: C57BL/6 * DBA/2)
|
increased pancreas adenoma incidence
|
J:78026
|
increased pancreas tumor incidence
|
J:78026
|
increased pancreatic acinar cell carcinoma incidence
|
J:78026
|
Tg(Ela1-TAg*)79Mjt/0 Tg(MUC1)79.24Gend/0
(involves: C57BL/6 * DBA/2)
|
increased pancreas adenoma incidence
|
J:64570
|
increased pancreas tumor incidence
|
J:64570
|
increased pancreatic acinar cell carcinoma incidence
|
J:64570
|
Tg(Ela1-TAg*)289Mjt/0
(involves: C57BL/6 * DBA/2)
|
increased pancreas adenoma incidence
|
J:78026
|
increased pancreas tumor incidence
|
J:78026
|
increased pancreatic acinar cell carcinoma incidence
|
J:78026
|
Tg(Ela1-Tgfa)150Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:52757,
J:67389
|
Tg(Ela1-Tgfa)150Bri/0 Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:67389
|
Tg(Ela1-Tgfa)150Bri/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:67389
|
increased pancreatic ductal adenocarcinoma incidence
|
J:67389
|
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Ela-KRAS*G12D)9Eps/0 Tg(Mt1-TGFBR2*)AM3Epb/0
(involves: C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Ela-KRAS*G12D)9Eps/0 Tgfbr1tm1Bopa/Tgfbr1+
(involves: 129S1/SvImJ * C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Emu-Pim1)64aBrn/0
(involves: C57BL/6LiA * CBA)
|
increased T cell derived lymphoma incidence
|
J:79624
|
Tg(Erbb2*)#Maed/0 Tg(Foxa3-cre)1Khk/0
(involves: C57BL/6 * C57BL/6J * DBA)
|
increased pancreas tumor incidence
|
J:262746
|
Tg(Erbb2-Erbb2*V664E)#Led/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62441
|
increased mammary gland tumor incidence in breeding females
|
J:62441
|
Tg(Gcg-TAg)25Ddr/?
(involves: CD-1)
|
increased pancreas tumor incidence
|
J:91490,
J:101537
|
Tg(Ggamma-T)15Cps/0
(involves: C57BL/6J * CBA/J)
|
increased adrenal gland tumor incidence
|
J:38778
|
increased prostate gland tumor incidence
|
J:38778
|
increased prostate intraepithelial neoplasia incidence
|
J:38778
|
increased testis tumor incidence
|
J:38778
|
Tg(Ggamma-T)15Cps/Tg(Ggamma-T)15Cps
(involves: C57BL/6J * CBA/J)
|
increased adrenal gland tumor incidence
|
J:38778
|
increased prostate gland tumor incidence
|
J:38778
|
increased prostate intraepithelial neoplasia incidence
|
J:38778
|
increased testis tumor incidence
|
J:38778
|
Tg(Gh-Gal)4599Vron/?
(involves: C57BL/6 * CD-1 * SJL)
|
increased pituitary adenoma incidence
|
J:86486
|
Tg(GHRL-TAg)1-5Hiwa/0
(C57BL/6-Tg(GHRL-TAg)1-5Hiwa)
|
increased pancreas tumor incidence
|
J:152492
|
increased thyroid tumor incidence
|
J:152492
|
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727,
J:184212
|
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0 Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727
|
Tg(Igh*-Mir125b-1)116Toki/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:178816
|
Tg(Igh-Mir155)8Cro/0
(involves: FVB/N)
|
increased lymphoblastic lymphoma incidence
|
J:109591
|
Tg(Igh-Pim1)1Brn/0
(involves: C57BL/6LiA * CBA)
|
increased T cell derived lymphoma incidence
|
J:79624
|
Tg(Ins1-Tag,-luc)1Gcr/0
(FVB/N-Tg(Ins1-Tag,-luc)1Gcr)
|
increased insulinoma incidence
|
J:162648
|
Tg(Ins1-Tag,-luc)1Gcr/0
(involves: C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:162648
|
Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Tg(Ins2-Akt1*)3Mbb)
|
increased insulinoma incidence
|
J:144599
|
increased pancreas tumor incidence
|
J:144599
|
increased pancreatic islet cell carcinoma incidence
|
J:144599
|
Tg(Ins2-IGF1R)1Dh/0 Tg(RIP1-Tag)2Dh/0
(involves: C3H * C57BL/6 * C57BL/6J * DBA/2J)
|
increased insulinoma incidence
|
J:205389
|
increased pancreatic islet cell carcinoma incidence
|
J:205389
|
Tg(Ins2-rtTA)2Efr/0 Tg(tetO-TAg)1Efr/0
(involves: C3HeB/FeJ * C57BL/6 * CBA)
|
increased insulinoma incidence
|
J:130049
|
Tg(Ins2-TAg)1Lt/0
(NOD/ShiLt-Tg(Ins2-TAg)1Lt)
|
increased insulinoma incidence
|
J:92449
|
Tg(Ins2-Tag*,-flpe)#Gne/0
(involves: C57BL/6J)
|
increased insulinoma incidence
|
J:187012
|
increased pancreas tumor incidence
|
J:187012
|
increased pancreatic islet cell carcinoma incidence
|
J:187012
|
Tg(Ins2-Tag*,-flpe)#Gne/0
(Not Specified)
|
increased pancreatic islet cell carcinoma incidence
|
J:188693
|
Tg(K5-Ptgs2)19Kmd/0
(involves: NMRI)
|
increased sebaceous gland adenoma incidence
|
J:79071
|
Tg(K5-Ptgs2)667Kmd/0
(involves: NMRI)
|
increased sebaceous gland adenoma incidence
|
J:79071
|
Tg(KRT14-Edn3)1Takk/?
(B6.Cg-Tg(KRT14-Edn3)1Takk)
|
increased thyroid tumor incidence
|
J:104881
|
Tg(KRT14-HPV16E7)2326Plam/0
(involves: FVB/N)
|
increased sebaceous gland tumor incidence
|
J:86018
|
Tg(KRT14-Snai1)1Efu/0
(involves: CD-1)
|
increased sebaceous gland tumor incidence
|
J:229072
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0
(involves: C57BL/6 * DBA/2)
|
increased ovarian carcinoma incidence
|
J:189304
|
increased ovary tumor incidence
|
J:189304
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Tg(KRT19-TAg)7Eps/0
(involves: FVB/N)
|
increased adrenal gland tumor incidence
|
J:64395
|
increased prostate gland tumor incidence
|
J:64395
|
Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:88120
|
Tg(Lck-Akt1*)M-1Pnt/0
(involves: C3H/He * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:73487
|
Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: C3H/He * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:73487
|
Tg(Lck-Akt1*E40K)E-3Pnt/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:144975
|
Tg(Lck-Akt2*)#Test/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:153923
|
Tg(Lck-Id1)28Xhsu/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:58607
|
Tg(Lck-LMO1)11Sjk/0 Tg(STIL-TAL1)A5(3)Alpa/0
(involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros)
|
increased T cell derived lymphoma incidence
|
J:40868
|
Tg(Lck-Map3k8)3456Ngc/?
(involves: C3H/HeJ * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:39450
|
Tg(Lck-Notch3)#Issc/0
(involves: C57BL/6 * DBA/2)
|
increased lymphoblastic lymphoma incidence
|
J:63300
|
increased T cell derived lymphoma incidence
|
J:96010
|
Tg(Lck-Tal1)4709Led/0
(FVB/N-Tg(Lck-Tal1)4709Led)
|
increased lymphoblastic lymphoma incidence
|
J:36076
|
Tg(Lck-Tax)53Hall/0
(involves: C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:129531
|
Tg(LckNotch1)9Erob/?
(involves: C57BL/6 * CBA/J)
|
increased T cell derived lymphoma incidence
|
J:93005
|
Tg(LCKprBCL2)36Sjk/?
(involves: C3H * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:28635
|
Tg(Ly6a-BCR/ABL1)IS1AIsg/0
(involves: C57BL/6J * CBA)
|
increased testis tumor incidence
|
J:144382
|
Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA)
|
increased testis tumor incidence
|
J:144382
|
Tg(MCL1)8Caig/0
(involves: C57BL/6 * SJL)
|
increased T cell derived lymphoma incidence
|
J:69755
|
Tg(Mdm2)1Snj/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased pituitary adenoma incidence
|
J:51661
|
Tg(MMTV-AURKA)#Cxd/?
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:145680
|
increased ovary tumor incidence
|
J:145680
|
Tg(MMTV-AURKA)#Cxd/? Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:145680
|
Tg(MMTV-CCND1)1Esmp/0
(Not Specified)
|
increased mammary adenoacanthoma incidence
|
J:70571
|
increased mammary adenocarcinoma incidence
|
J:70571
|
increased mammary gland tumor incidence
|
J:70571
|
increased testis tumor incidence
|
J:70571
|
Tg(MMTV-CCND1)1Esmp/0 Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62465
|
increased mammary gland tumor incidence
|
J:62465
|
Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary adenoacanthoma incidence
|
J:62465
|
increased mammary adenocarcinoma incidence
|
J:62465
|
Tg(MMTV-Cdc37)1Stp/0 Tg(MMTV-Myc)141-3Led/0
(involves: C57BL/6 * CD-1 * DBA/2 * FVB/N)
|
increased Leydig cell tumor incidence
|
J:62465
|
increased mammary adenocarcinoma incidence
|
J:62465
|
increased mammary gland tumor incidence
|
J:62465
|
increased salivary adenocarcinoma incidence
|
J:62465
|
Tg(MMTV-Cdc37)2Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary adenoacanthoma incidence
|
J:62465
|
Tg(MMTV-DMTF1_i2)7Kai/0
(FVB/NJ-Tg(MMTV-DMTF1_i2)7Kai)
|
increased mammary gland tumor incidence in breeding females
|
J:220608
|
Tg(MMTV-ENPP2)20Gbm/0
(FVB/N-Tg(MMTV-ENPP2)20Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-ENPP2)21Gbm/0
(FVB/N-Tg(MMTV-ENPP2)21Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-ENPP2)#Gbm/0
(FVB/N-Tg(MMTV-ENPP2)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-Erbb2)1Pv/0
(involves: BALB/c * C57BL/6 * CD-1 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:234420
|
Tg(MMTV-ERBB2)5Erick/?
(FVB/N-Tg(MMTV-ERBB2)5Erick)
|
increased Harderian gland adenoma incidence
|
J:90202
|
increased mammary adenocarcinoma incidence
|
J:90202
|
increased mammary gland tumor incidence
|
J:90202
|
Tg(MMTV-Erbb2)9Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)10Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased Harderian gland tumor incidence
|
J:72129
|
increased mammary adenocarcinoma incidence
|
J:72129
|
increased salivary gland tumor incidence
|
J:72129
|
Tg(MMTV-Erbb2)12Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
increased salivary gland tumor incidence
|
J:72129
|
Tg(MMTV-Erbb2)17Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)NA1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(involves: CD-1 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NF1Mul)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NK1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:76653
|
Tg(MMTV-Erbb2)NK1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NK1Mul)
|
increased mammary gland tumor incidence
|
J:67457
|
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: C57BL/6)
|
increased mammary gland tumor incidence
|
J:189292
|
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:198481
|
Tg(MMTV-ERBB2*,-luc)6157Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6157Aami)
|
increased mammary adenocarcinoma incidence
|
J:172352
|
increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB2*,-luc)6177Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6177Aami)
|
increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB2*,-luc)6180Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6180Aami)
|
increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB3)1Slg/0 Tg(MMTVneu)202Mul/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:80974
|
Tg(MMTV-Espl1)1Pati/0
(involves: C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:216267
|
increased mammary gland tumor incidence in breeding females
|
J:216267
|
Tg(MMTV-KRAS*G12V)3025Mrl/0
(involves: C57BL/6 * FVB * SJL)
|
increased mammary adenocarcinoma incidence
|
J:77272
|
Tg(MMTV-KRAS*G12V)3025Mrl/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-MYC)1Lach/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-LPAR1)2Gbm/Tg(MMTV-LPAR1)2Gbm
(FVB/N-Tg(MMTV-LPAR1)2Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)7Gbm/Tg(MMTV-LPAR1)7Gbm
(FVB/N-Tg(MMTV-LPAR1)7Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)27Gbm/Tg(MMTV-LPAR1)27Gbm
(FVB/N-Tg(MMTV-LPAR1)27Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)#Gbm/Tg(MMTV-LPAR1)#Gbm
(FVB/N-Tg(MMTV-LPAR1)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR2)3Gbm/Tg(MMTV-LPAR2)3Gbm
(FVB/N-Tg(MMTV-LPAR2)3Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR2)6Gbm/Tg(MMTV-LPAR2)6Gbm
(FVB/N-Tg(MMTV-LPAR2)6Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR2)#Gbm/Tg(MMTV-LPAR2)#Gbm
(FVB/N-Tg(MMTV-LPAR2)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR3)3Gbm/Tg(MMTV-LPAR3)3Gbm
(FVB/N-Tg(MMTV-LPAR3)3Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR3)22Gbm/Tg(MMTV-LPAR3)22Gbm
(FVB/N-Tg(MMTV-LPAR3)22Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR3)#Gbm/Tg(MMTV-LPAR3)#Gbm
(FVB/N-Tg(MMTV-LPAR3)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-Myc)141-3Led/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Kras2)12Hev/0
(involves: C57BL/6J * CD-1 * FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-Myc)WT13Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-Myc)WT21Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-Myc*T58A)TA14Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-Myc*T58A)TA39Jrn/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:193362
|
Tg(MMTV-Myc*T58A)TA41Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-NCOA3)#Mybr/0
(FVB/N-Tg(MMTV-NCOA3)#Mybr)
|
increased mammary adenocarcinoma incidence
|
J:93548
|
increased mammary gland tumor incidence
|
J:93548
|
increased pituitary adenoma incidence
|
J:93548
|
Tg(MMTV-neu/OT-I/OT-II)CBnel/?
(involves: C57BL/6)
|
increased mammary gland tumor incidence
|
J:122846
|
Tg(MMTV-neu/OT-I/OT-II)CBnel/? Tg(Trp53R172H)8512Jmr/?
(involves: C57BL/6 * FVB)
|
increased mammary adenocarcinoma incidence
|
J:122846
|
Tg(MMTV-Notch4)3Rnc/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:11644
|
increased salivary adenocarcinoma incidence
|
J:11644
|
Tg(MMTV-PTGS2)#Thla/0
(involves: CD-1)
|
increased mammary adenocarcinoma incidence
|
J:68565
|
increased mammary gland ductal carcinoma incidence
|
J:68565
|
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/Nci)
|
increased mammary adenocarcinoma incidence
|
J:46460,
J:51424,
J:87544,
J:48285
|
Tg(MMTV-PyVT)634Mul/0
(multiple strains)
|
increased mammary adenocarcinoma incidence
|
J:48854
|
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/J)
|
increased mammary gland tumor incidence
|
J:140033,
J:147458
|
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:147458
|
Tg(MMTV-PyVT)634Mul/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133325,
J:236031
|
Tg(MMTV-PyVT)#Mul/0
(B6.FVB-Tg(MMTV-PyVT)#Mul)
|
increased mammary adenocarcinoma incidence
|
J:147923
|
Tg(MMTV-PyVT*Y250F)250-2Mul/?
(FVB/N-Tg(MMTV-PyVT*Y250F)250-2Mul)
|
increased mammary adenocarcinoma incidence
|
J:56327
|
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(FVB/N-Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul)
|
increased mammary adenocarcinoma incidence
|
J:56327
|
Tg(MMTV-rtTA)1Lach/0 Tg(TetO-Erbb2)1Lach/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:81083
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-ERBB2)#Jjz/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:231766
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Esr1)#Paf/0
(involves: FVB/N)
|
increased mammary gland ductal carcinoma incidence
|
J:96383
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-IGF1R)1Ramo/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:121069
|
increased mammary gland tumor incidence
|
J:121069
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Kras2)12Hev/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Kras2)12Hev/0 Tg(tetO-MYC)1Lach/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-MYC)1Lach/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:67498
|
increased mammary gland tumor incidence
|
J:133578,
J:67498
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-PIK3CA*H1047R,-luc)2239Jjz/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:175839
|
increased mammary gland tumor incidence
|
J:175839
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-PyVT,-cre)1Mul/0
(FVB/N-Tg(MMTV-rtTA)1Lach Tg(tetO-PyVT,-cre)#Mul)
|
increased mammary adenocarcinoma incidence
|
J:231983
|
increased mammary gland tumor incidence in virgin females
|
J:231983
|
Tg(MMTV-TGFBR2)7Hlm/? Tg(MMTVTGFA)29Rjc/?
(involves: C57BL/6 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:85799
|
Tg(MMTV-TGFBR2)7Hlm/Tg(MMTV-TGFBR2)7Hlm
(involves: C57BL/6 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:85799
|
Tg(MMTV-vHaras)SH1Led/0
(involves: C57BL/6J * CD-1)
|
increased mammary gland tumor incidence
|
J:88789
|
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129X1/SvJ * C57BL/6J * CD-1 * FVB)
|
increased mammary adenocarcinoma incidence
|
J:86074
|
Tg(MMTVneu)202Mul/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:35344,
J:80974
|
Tg(MMTVneu)202Mul/0
(FVB/N-Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:56332
|
Tg(MMTVneu)202Mul/0 Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary gland tumor incidence
|
J:35344
|
Tg(MMTVneu)202Mul/0 Tg(Trp53R172H)8512Jmr/0
(C.FVB-Tg(MMTVneu)202Mul Tg(Trp53R172H)8512Jmr)
|
increased mammary adenocarcinoma incidence
|
J:115041
|
increased parotid gland tumor incidence
|
J:115041
|
Tg(MMTVneu)202Mul/0 Tg(Trp53R172H)8512Jmr/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:40336
|
Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary adenocarcinoma incidence
|
J:72085,
J:72080,
J:28453,
J:71696
|
increased mammary gland tumor incidence
|
J:28453,
J:71696
|
Tg(MMTVTGFA)64Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary gland tumor incidence
|
J:72085
|
Tg(MMTVTGFA)254Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary adenocarcinoma incidence
|
J:72085
|
Tg(Msmb-TAg)183-2Xuan/0
(involves: C57BL/6 * CBA)
|
increased prostate gland adenocarcinoma incidence
|
J:80313
|
increased prostate intraepithelial neoplasia incidence
|
J:80313
|
Tg(Mt1-Tgfa)147Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(Mt1-Tgfa)149Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:162125
|
Tg(MtTGFA)100Lmb/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:72083
|
increased mammary gland tumor incidence
|
J:72083
|
Tg(MtTGFA)Lmb/0
(involves: CD-1)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:229184
|
Tg(MtTPRMET)243Lng/0
(FVB/N-Tg(MtTPRMET)243Lng)
|
increased mammary gland tumor incidence
|
J:71573
|
Tg(MtTPRMET)773Lng/0
(FVB/N-Tg(MtTPRMET)773Lng)
|
increased mammary gland tumor incidence
|
J:71573
|
Tg(OMP-SV40T)13Bse/0
(involves: C57BL/6 * SJL)
|
increased adrenal gland tumor incidence
|
J:54269
|
Tg(Pbsn-Ar*E231G)7353Ng/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:96117
|
increased prostate gland tumor incidence
|
J:96117
|
Tg(Pbsn-ERG*)1Vv/0
(involves: 129/Sv * C57BL/6J * CBA)
|
increased prostate intraepithelial neoplasia incidence
|
J:131932
|
Tg(Pbsn-ERG*)1Vv/0
(involves: 129S1/SvImJ * C57BL/6J * CBA)
|
increased prostate gland adenocarcinoma incidence
|
J:222916
|
increased prostate gland tumor incidence
|
J:222916
|
Tg(Pbsn-FGF7)3293Ng/0
(Not Specified)
|
increased prostate intraepithelial neoplasia incidence
|
J:80821
|
Tg(Pbsn-FGFR1*K656E)#Wmck/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87519
|
Tg(Pbsn-FGFR1*K656E)#Wmck/0 Tg(Pbsn-FGFR2_iiib*)#Ng/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(FVB-Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp)
|
increased prostate gland adenocarcinoma incidence
|
J:130340
|
increased prostate gland tumor incidence
|
J:130340
|
increased prostate intraepithelial neoplasia incidence
|
J:130340,
J:87092
|
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0 Tg(Pbsn-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727
|
Tg(Pbsn-Hpn,-GFP)DVv/0 Tg(Pbsn-Tag)12T7fRjm/0
(involves: C57BL/6J * CBA * CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:92562
|
increased prostate intraepithelial neoplasia incidence
|
J:92562
|
Tg(Pbsn-IGF1*)5305Ng/0
(involves: FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:144539
|
Tg(Pbsn-IGF1*)5305Ng/0 Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * FVB/N)
|
increased prostate gland tumor incidence
|
J:144539
|
Tg(Pbsn-MYC)6Key/?
(involves: FVB)
|
increased prostate gland adenocarcinoma incidence
|
J:85480
|
increased prostate gland tumor incidence
|
J:85480
|
increased prostate intraepithelial neoplasia incidence
|
J:85480
|
Tg(Pbsn-MYC)#Tt/?
(involves: C57BL/6J)
|
increased prostate gland adenocarcinoma incidence
|
J:205395
|
increased prostate intraepithelial neoplasia incidence
|
J:205395
|
Tg(Pbsn-Tag)12T7fRjm/0
(involves: CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:48623
|
increased prostate gland tumor incidence
|
J:48623
|
increased prostate intraepithelial neoplasia incidence
|
J:92562,
J:48623
|
Tg(Pbsn-Tag)12T10Rjm/0
(involves: CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:68483,
J:48623
|
increased prostate gland tumor incidence
|
J:48623
|
increased prostate intraepithelial neoplasia incidence
|
J:68483
|
Tg(Pbsn-TAg)15Tvd/0
(involves: C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:103408
|
increased prostate intraepithelial neoplasia incidence
|
J:103408
|
Tg(Pim1-Il9)5Jcrd/0
(involves: FVB/N)
|
increased T cell derived lymphoma incidence
|
J:17848
|
Tg(Pklr-SV40)1Ak/0
(involves: C57BL/6 * DBA)
|
increased insulinoma incidence
|
J:185488
|
increased pancreas tumor incidence
|
J:185488
|
Tg(Pklr-SV40)1Ak/Tg(Pklr-SV40)1Ak
(involves: C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:185488
|
Tg(Prl-EGFR)#Sme/0
(Not Specified)
|
increased prolactinoma incidence
|
J:219654
|
Tg(PTH-CCND1)PC2Anar/0
(FVB/N-Tg(PTH-CCND1)PC2Anar)
|
increased parathyroid adenoma incidence
|
J:69423
|
Tg(PyLT)1Vb/0
(Not Specified)
|
increased pituitary adenoma incidence
|
J:55528
|
increased pituitary gland tumor incidence
|
J:55528
|
Tg(Rbp3-SV40)IT-2Jjw/?
(involves: BALB/c * C57BL/6)
|
increased pineal gland tumor incidence
|
J:60231
|
Tg(RIP1-Tag)2Dh/?
(C3.Cg-Tg(RIP1-Tag)2Dh/Nci)
|
increased insulinoma incidence
|
J:80168
|
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6)
|
increased insulinoma incidence
|
J:162648
|
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6J * DBA/2J)
|
increased insulinoma incidence
|
J:205389
|
increased pancreas tumor incidence
|
J:50695
|
increased pancreatic islet cell carcinoma incidence
|
J:205389
|
Tg(RIP1-Tag)5Dh/?
(C3HeB/FeJ-Tg(RIP1-Tag)5Dh)
|
increased insulinoma incidence
|
J:80168
|
Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh)
|
increased insulinoma incidence
|
J:136259
|
Tg(RIR-Tag)87Dh/0
(involves: C57BL/6J * DBA/2J)
|
increased pancreas tumor incidence
|
J:50695
|
Tg(rTH-Tag)20Dmc/0
(involves: C57BL/6NTac * DBA/2NTac)
|
increased adrenal gland tumor incidence
|
J:90323
|
Tg(Smgb-TAg)8Mir/Tg(Smgb-TAg)8Mir
(involves: BALB/cJ * C57BL/6J)
|
increased salivary adenocarcinoma incidence
|
J:66189
|
Tg(SV40-NRAS*G12D)1Sco/?
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:125150
|
Tg(SV)419Bri/Tg(SV)419Bri
(C57BL/6J-Tg(SV)419Bri)
|
increased T cell derived lymphoma incidence
|
J:147031
|
Tg(TCF3/HLF)1Mlc/0
(involves: FVB/N)
|
increased T cell derived lymphoma incidence
|
J:55022
|
Tg(Tcra,Tcrb)HRVAll/0 Tg(TRAMP)8247Ng/0
(B6.Cg-Tg(TRAMP)8247Ng Tg(Tcra,Tcrb)HRVAll)
|
increased prostate gland tumor incidence
|
J:131347
|
Tg(Tek-cre)1Ywa/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased T cell derived lymphoma incidence
|
J:263520
|
Tg(tetO-BRAF*V600E)26Jaf/0 Tg(TG-rtTA)30Jaf/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:184420
|
increased thyroid tumor incidence
|
J:184420
|
Tg(tetO-TAg)2-5Hiwa/0
(involves: C57BL/6)
|
increased adrenal gland tumor incidence
|
J:175962
|
Tg(TG-BRAF*V600E)2Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)2Jaf)
|
increased thyroid carcinoma incidence
|
J:98550
|
increased thyroid tumor incidence
|
J:98550
|
Tg(TG-BRAF*V600E)3Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)3Jaf)
|
increased thyroid carcinoma incidence
|
J:98550
|
Tg(TG-NRAS*Q61K)#Msnt/0
(Not Specified)
|
increased thyroid adenoma incidence
|
J:210016
|
increased thyroid carcinoma incidence
|
J:210016
|
Tg(TG-RET/CCDC6)1Cled/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:55883,
J:93679
|
Tg(TG-RET/CCDC6)42Cled/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:55883,
J:93679
|
Tg(TG-RET/NCOA4)3209Rstn/0
(involves: C57BL/6)
|
increased thyroid carcinoma incidence
|
J:51366
|
Tg(TG-SV40)#Cled/0
(involves: C57BL/6J * DBA/2J)
|
increased thyroid carcinoma incidence
|
J:209788
|
Tg(TG-TPR/NTRK1)5215Rstn/0
(involves: C3H * C57BL/6)
|
increased thyroid carcinoma incidence
|
J:67120
|
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Tg(Th-TAg)17Dmc/0
((C57BL/6NTac x DBA/2NTac)F2)
|
increased adrenal gland tumor incidence
|
J:90323
|
Tg(Thy1-cmyc)6Kio/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:129440
|
Tg(Thy1-cmyc)6LKio/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:129440
|
Tg(Tnfsf13b)1Fma/0
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
increased submandibular gland tumor incidence
|
J:73711
|
Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Tg(TRAMP)8247Ng/0
(involves: C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:217920,
J:65303
|
Tg(TRAMP)8247Ng/0
(involves: C3H * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:125633
|
increased prostate gland tumor incidence
|
J:125633
|
increased prostate intraepithelial neoplasia incidence
|
J:125633
|
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
increased prostate gland tumor incidence
|
J:133908
|
increased prostate intraepithelial neoplasia incidence
|
J:133908,
J:131932
|
Tg(TRAMP)8247Ng/0 Usp11tm1Tac/Y
(involves: 129 * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:270214
|
increased prostate intraepithelial neoplasia incidence
|
J:270214
|
Tg(Trp53R172H)8512Jmr/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:46426
|
Tg(Vav1-Lin28b)C3Apla/0
(involves: C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:189197
|
Tg(Vav-BCL2)69Jad/0
(involves: C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:88565
|
Tg(Wap-Hgf)402Mig/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:86776
|
increased mammary gland tumor incidence in breeding females
|
J:86776
|
increased mammary gland tumor incidence in virgin females
|
J:86776
|
Tg(Wap-Hgf)402Mig/0
(FVB/N-Tg(Wap-Hgf)402Mig)
|
increased mammary adenocarcinoma incidence
|
J:206839
|
increased mammary gland tumor incidence in breeding females
|
J:206839
|
X/Tg(Wap-HRAS)69Lln
(involves: C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:46458
|
increased salivary adenocarcinoma incidence
|
J:46458
|
X/Tg(Wap-HRAS)69Lln
(FVB.Cg-Tg(Wap-HRAS)69Lln Chr YSJL/J)
|
increased mammary gland tumor incidence
|
J:101113
|
Tg(Wap-TAg)1Depp/0
(involves: BALB/c * C57BL/6)
|
increased mammary gland ductal carcinoma incidence
|
J:61012
|
Tg(Wap-tAg)1Gmn/?
(involves: NMRI)
|
increased mammary adenocarcinoma incidence
|
J:69711
|
Tg(Wap-TAg)12Gmn/?
(involves: NMRI)
|
increased mammary gland tumor incidence
|
J:69711
|
Tg(Wap-TAg)NP8Depp/0
(involves: BALB/c * C57BL/6)
|
increased mammary gland ductal carcinoma incidence
|
J:61012
|
Tg(Wap-Tsg101)4389Kuw/0
(FVB/N-Tg(Wap-Tsg101)4389Kuw)
|
increased mammary adenocarcinoma incidence
|
J:121475
|
Tg(WapMyc)212Bri/0
(FVB.Cg-Tg(WapMyc)212Bri)
|
increased mammary gland tumor incidence
|
J:114568
|
Tg(WapMyc)212Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(WapMyc)212Bri/0 Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(WapNotch4)10Rnc/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:33193
|
Tg(WapTAg)1Knw/0
(C57BL/6J-Tg(WapTAg)1Knw/J)
|
increased mammary adenocarcinoma incidence
|
J:53175
|
Tg(WapTAg)3Knw/0
(C57BL/6J-Tg(WapTAg)3Knw)
|
increased mammary adenocarcinoma incidence
|
J:53175
|
Tg(WapTgfa)215Bri/0
(FVB.Cg-Tg(WapTgfa)215Bri)
|
increased mammary gland tumor incidence
|
J:114568
|
Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(WapTgfa)215Bri/0
(B6.Cg-Tg(WapTgfa)215Bri)
|
increased mammary gland tumor incidence
|
J:123146
|
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:54215
|
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:61009
|
Tgct1MOLF/Ei/Tgct1MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct2MOLF/Ei/Tgct2MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct3MOLF/Ei/Tgct3MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct5MOLF/Ei/Tgct5MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tg(Col1a2-cre/ERT,-ALPP)7Cpd/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:204736
|
increased prostate intraepithelial neoplasia incidence
|
J:204736
|
Thbs1tm1Hyn/Thbs1tm1Hyn Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72391
|
increased pancreas tumor incidence
|
J:72391
|
Thbs1tm1Hyn/Thbs1tm1Hyn Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased pancreas tumor incidence
|
J:72391
|
ThimTg(Myh6-TGFB1)1Ljf/Thim+
(involves: C3HeB/FeJ)
|
increased T cell derived lymphoma incidence
|
J:59903
|
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
|
increased pituitary adenoma incidence
|
J:95391
|
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:92629
|
Thrbtm1Df/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:92629
|
Thyls2MSM/Thyls2MSM
(involves: BALB/c * MSM)
|
increased T cell derived lymphoma incidence
|
J:87704
|
Tlag2AKR/J/Tlag2C57L/J
(involves: AKR/J * C57L/J)
|
increased T cell derived lymphoma incidence
|
J:74369
|
Tlag2AKR/J/Tlag2C57L/J Tlag1AKR/J/Tlag1AKR/J
(involves: AKR/J * C57L/J)
|
increased T cell derived lymphoma incidence
|
J:74369
|
Tlsm1AKR/JMs/Tlsm1AKR/JMs
(involves: AKR/JMs * SL/Kh)
|
increased T cell derived lymphoma incidence
|
J:21741,
J:41197,
J:33016
|
Tlsm1AKR/JMs/Tlsm1SL/Kh
(involves: AKR/JMs * SL/Kh)
|
increased T cell derived lymphoma incidence
|
J:21741,
J:41197,
J:33016
|
Tnk1tm1Sksuf/Tnk1+
(involves: 129X1/SvJ * C57BL/6)
|
increased pancreas tumor incidence
|
J:140639
|
Tom1l2Gt(XG909)Byg/Tom1l2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased prostate gland tumor incidence
|
J:133892
|
Tom1l2Gt(XG909)Byg/Tom1l2Gt(XG909)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:133892
|
increased ovary tumor incidence
|
J:133892
|
increased prostate gland tumor incidence
|
J:133892
|
Trim37Gt(RRO307)Byg/Trim37Gt(RRO307)Byg
(B6J.129P2-Trim37Gt(RRO307)Byg)
|
increased ovary tumor incidence
|
J:232482
|
Trim62tm1Akil/Trim62+
(involves: 129S/SvEv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:204336
|
Trim62tm1Akil/Trim62tm1Akil
(involves: 129S/SvEv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:204336
|
Trp53Bbl/Trp53+
(C57BL/6JSfdAnu-Trp53Bbl/Anu)
|
increased T cell derived lymphoma incidence
|
J:104190
|
Trp53bhy/Trp53+
(C57BL/6JSfdAnu-Trp53bhy/Anu)
|
increased T cell derived lymphoma incidence
|
J:104190
|
Trp53tm1.1Awbr/Trp53tm1.1Awbr
(involves: C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:173271
|
Trp53tm1.1Thst/Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased T cell derived lymphoma incidence
|
J:198482
|
Trp53tm1.1Umol/Trp53tm1.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1.2Awbr/Trp53+
(involves: C57BL/6)
|
increased ovary tumor incidence
|
J:173271
|
Trp53tm1.2Awbr/Trp53tm1.2Awbr
(involves: C57BL/6)
|
increased ovary tumor incidence
|
J:173271
|
increased T cell derived lymphoma incidence
|
J:173271
|
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:126497
|
Trp53tm1Brd/Trp53tm1Brd Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:157041
|
Trp53tm1Brd/Trp53tm1Brd Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased T cell derived lymphoma incidence
|
J:109585
|
Trp53tm1Brd/Trp53tm1Ldo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:73757
|
Trp53tm1Brn/Trp53+ Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
increased mammary gland tumor incidence
|
J:170898
|
Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
increased mammary gland tumor incidence
|
J:126551
|
Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Tg(MMTV-cre)105Ayn)
|
increased mammary gland tumor incidence
|
J:165292
|
Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary gland tumor incidence
|
J:162126
|
Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:171765
|
increased mammary gland tumor incidence
|
J:171765
|
Trp53tm1Elee/Trp53tm1Elee Tg(MMTV-cre)AElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
increased mammary gland tumor incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee Tg(MMTV-cre)BElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee Tg(Wap-rtTA-cre)10Whl/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:99305
|
Trp53tm1Glo/Trp53tm1Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:61683
|
Trp53tm1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:171821
|
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:36762
|
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
increased T cell derived lymphoma incidence
|
J:233347
|
Trp53tm1Thst/Trp53tm1Thst
(involves: 129S1/Sv * 129X1/SvJ)
|
increased T cell derived lymphoma incidence
|
J:198482
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72391
|
increased pancreas tumor incidence
|
J:72391
|
Trp53tm1Tyj/Trp53+ Trp63tm1Fmc/Trp63+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:98958
|
increased T cell derived lymphoma incidence
|
J:98958
|
Trp53tm1Tyj/Trp53+ Trp73tm1Fmc/Trp73+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased pancreatic acinar cell carcinoma incidence
|
J:98958
|
increased T cell derived lymphoma incidence
|
J:98958
|
Trp53tm1Tyj/Trp53+ Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:111068
|
Trp53tm1Tyj/Trp53tm1.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:87501,
J:17728
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased T cell derived lymphoma incidence
|
J:251434,
J:221224,
J:88120,
J:95316
|
Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
|
increased testicular teratoma incidence
|
J:102483
|
Trp53tm1Tyj/Trp53tm1Tyj Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:111068
|
Trp53tm1Tyj/Trp53tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:95316
|
Trp53tm1Tyj/Trp53tm2.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1Tyj/Trp53tm3.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:95316
|
Trp53tm2.1Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased T cell derived lymphoma incidence
|
J:282255
|
increased testis tumor incidence
|
J:282255
|
Trp53tm2.1Umol/Trp53tm2.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm2Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased T cell derived lymphoma incidence
|
J:282255
|
increased testis tumor incidence
|
J:282255
|
Trp53tm3.1Glo/Trp53+
(B6.129S7-Trp53tm3.1Glo)
|
increased T cell derived lymphoma incidence
|
J:317504
|
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * SKH1)
|
increased mammary adenocarcinoma incidence
|
J:121734
|
Trp53tm3Tyj/Trp53+ Tg(Wap-cre)11738Mam/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:101617
|
increased mammary gland tumor incidence
|
J:101617
|
Trp53tm4Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:171821
|
Trp53tm4Xu/Trp53tm4Xu
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:126497
|
Trp53tm6Xu/Trp53tm6Xu Tg(Lck-cre)1Cwi/0
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:157041
|
Trp53bp1tm1Jc/Trp53bp1tm1Jc
(involves: 129 * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:82512
|
Trp53bp2tm1Cdlo/Trp53bp2+ Tg(EmuSR-tTa)83Bop/0 Tg(tetO-MYC)36aBop/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:146764
|
Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:108701
|
Trp63tm1Fmc/Trp63+ Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:98958
|
increased salivary gland adenoma incidence
|
J:98958
|
increased T cell derived lymphoma incidence
|
J:98958
|
Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:98958
|
Trp73tm1Mak/Trp73+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:142848
|
Trp73tm1Mak/Trp73tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:142848
|
Uimc1tm1.2Amj/Uimc1tm1.2Amj
(involves: BALB/cJ * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:191827
|
Vhltm1Lss/Vhltm1Lss Tg(Pdx1-cre)89.1Dam/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased pancreas adenoma incidence
|
J:148174
|
Xrcc6tm1Fwa/Xrcc6tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:44361
|
Zeb1tm1Yhi/Zeb1tm1Yhi
(either: (involves: 129 * C3H * C57BL/6) or (involves: 129 * C57BL/6 * ICR))
|
increased T cell derived lymphoma incidence
|
J:139194
|
Zfhx3tm1.1Jtd/Zfhx3tm1.1Jtd Tg(Pbsn-cre)4Prb/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
|
increased prostate intraepithelial neoplasia incidence
|
J:189563
|
Zfp36l1tm1.1Tnr/Zfp36l1tm1.1Tnr Zfp36l2tm1.1Tnr/Zfp36l2tm1.1Tnr Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL)
|
increased T cell derived lymphoma incidence
|
J:162388
|